

This is a “preproof” accepted article for *Animal Nutriomics*.  
This version may be subject to change during the production process.  
10.1017/anr.2024.9

## **Impacts of Epigenetic Reprogramming on Innate Immunity**

Jie Fu<sup>1,2</sup> and Yizhen Wang<sup>1,2\*</sup>

<sup>1</sup>Key Laboratory of Molecular Animal Nutrition, Ministry of Education, College of Animal Sciences, Zhejiang University, Hangzhou, China.

<sup>2</sup>Key Laboratory of Animal Nutrition and Feed Science in Eastern China, Ministry of Agriculture, Hangzhou, Zhejiang Province, China.

\*E-mail: yzwang321@zju.edu.cn (Y.W.)

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work

## **Abstract**

The innate immune response is the host's first line of defense, promptly activated upon pathogen invasion. Its precise and rapid activation relies on innate immune cells. Upon recognizing danger signals post-infection or injury, they release various innate immune effectors to eliminate invading pathogens or damaged cells, thus supporting the host's immune homeostasis. Epigenetic modifications, by shaping chromatin structures, orchestrate specific gene transcription patterns to regulate the lineage development, differentiation, and activation of innate immune cells. This intricate process ultimately contributes to effective pathogen clearance and innate immune cells' healthy development and differentiation. To thoroughly elucidate the epigenetic mechanisms underlying the development and differentiation of innate immune cells, this review first introduces the fundamental concepts and latest advancements in this field. We then delve into how the immune microenvironment or other signaling molecules shape the epigenetic landscapes of distinct innate immune cell subsets during their lineage development and differentiation. Furthermore, we summarize how different epigenetic modification profiles mediate specific transcriptional patterns, thereby influencing the lineage development, differentiation, and activation of innate immune cells in response to infections or injuries. Finally, we discuss several unresolved critical issues from the perspective of targeting epigenetic modifications to modulate the innate immune response. In summary, this review aims to uncover the molecular mechanisms underlying the development, differentiation, and activation of innate immune cells from an epigenetic perspective, providing theoretical foundations for scientific and medical researchers pursuing disease treatments.

**Keywords:** innate immunity, epigenetics, macrophage, dendritic cell, innate lymphoid cells

## **Introduction**

During differentiation, development, infection, stress, and damage repair, innate immune cells (IICs), including macrophages, dendritic cells (DCs), neutrophils, and

innate lymphoid cells (ILCs), assume specific gene expression patterns in response to the modulation of the local immune microenvironment<sup>[1]</sup>. These patterns confer distinct phenotypes and biological functions to the IICs. IICs recognize danger signals following infection or injury through pattern recognition receptors (PRRs), which can detect pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). Subsequently, IICs release various innate immune effectors to eliminate invading pathogens and damaged cells, contributing to the resolution of inflammation and the lineage development and differentiation of IICs<sup>[2,3]</sup>.

The phenotypes of IICs exhibit a remarkable degree of plasticity, and specific phenotypes confer corresponding functions on IICs<sup>[4,5]</sup>. Upon pathogen invasion, IICs swiftly convert from inactivated to activated phenotypes to facilitate the eradication of microbial invaders. Conversely, following pathogen clearance, activated IICs transition to a suppressed state, resulting in reduced inflammatory levels<sup>[1,6]</sup>. However, pathogen invasion or sterile inflammatory signals employ diverse strategies to disrupt the defensive capabilities of the innate immune system. The disruption results in compromised lineage development, differentiation, and subsequent activation of IICs, thereby allowing pathogens to parasitize the host. Dysregulation of innate immune responses can lead to outbreaks of organismal inflammation, subsequent diseases, and even mortality<sup>[7,8]</sup>. Therefore, deciphering the molecular mechanisms underlying the lineage development, differentiation, and activation of IICs, along with identifying effectors of innate immune responses, would help identify promising therapeutic targets to address dysregulated innate immune responses in infections and inflammatory diseases.

Epigenetic reshaping serves as the dynamic foundation to regulate gene expression (Figure 1). Chromatin status changes, mediated by histone modifications in enhancer and promoter regions, play a crucial role in the development, differentiation, and activation of IICs<sup>[9-11]</sup>. DNA methylation modifications at specific sites can either hinder or promote the binding of key transcription factors (TFs) responsible for fate conversion in IICs, inducing or impeding the transcription of

critical genes involved in lineage development, differentiation, and activation<sup>[12-15]</sup>. Histone modifications open up new chromatin accessibility regions, allowing DNA binding by specific transcription complexes or TFs, thereby initiating the transcriptional pattern of particular phenotypes in IICs<sup>[16,17]</sup>. Non-coding RNAs (ncRNAs) impact chromatin accessibility and downstream gene expression by interacting with promoters, enhancers, histones, and transcription complexes<sup>[18-20]</sup>. RNA m<sup>6</sup>A methylation not only regulates chromatin accessibility and transcription rate through co-transcriptional mechanisms but also influences the development and differentiation of IIC lineages and the activation of their key genes by mediating nascent RNA splicing and mRNA metabolism<sup>[21-23]</sup>. Relying on the transcriptional patterns of innate immunity-specific phenotypes mediated by epigenetic reshaping, IICs assume distinct phenotypes and biological functions to facilitate pathogen elimination, reduction of inflammatory levels, and healthy development and differentiation. High-throughput sequencing technology quantitatively reveals various epigenetic modification landscapes in different developmental stages and different activation states of IICs, enabling studies on the impact of epigenetics on the development and activation of innate immune cell lineages (Table 1). Epigenetic modifications allow precise and dynamic reversible control of IICs, and dysregulation in this process can lead to various diseases. Hence, considerable clinical potential resides in harnessing the power of epigenetic modifier enzymes, along with their specific inhibitors and activators, to manipulate the epigenetic modification profile of IICs for the treatment or prevention of infection and inflammation-related diseases.

This review aims to explore how the local ecological microenvironment shaped by the host following the development, differentiation, infection, or inflammatory damage of innate immune cell lineages, modulates the gene expression of epigenetic modification groups and their modifying enzymes. Additionally, it investigates how the epigenetic modifications shaped by the local microenvironment and their modifying enzymes reciprocally mediate specific gene expression patterns in IICs, contributing to the regulation of lineage development, differentiation, and timely response to infections and inflammation.

Table 1 Epigenomic techniques

Method	Description
<b>DNA methylation</b>	
WGBS, RRBS, oxBS-seq	Bisulfite treatment by sequencing method to identify genome-wide peaks of DNA methylation
MeDIP-seq, MDB-seq, hmeDIP-seq, 6mA-IP-seq	Specific antibody IP sequencing methods to identify genome-wide peaks of DNA methylation
<b>Histone modifications</b>	
Chip-seq, Cut-tag/Cut-Run	The study of intracellular protein-DNA interactions is also used to identify specific sites on the genome associated with histone modification, that is, the targets of histone-modifying enzymes
<b>Three-dimensional genome</b>	
3C, 4C,5C, Hi-C	Detect the high-level structure of chromosomes and specific regions of the genome and detect the interactions between different regions of the genome
Chip-loop, chIA-PET	To detect the interaction of genomic regions mediated by the target protein
<b>Chromatin</b>	
ATAC-seq, DNase-seq, FAIRE-seq, KAS-seq	The detection of open areas on chromatin directly reflects the accessibility of chromatin. N3-kethoxal directly marks the single-strand DNA being transcribed, and extraction of enriched DNA can reflect changes in chromatin accessibility, enhancer activity, and DNA topology
Mnase-seq	MNase-seq is a method that indirectly reflects chromatin accessibility by sequencing nucleosome-protected DNA
<b>RNA m<sup>6</sup>A methylation</b>	
miCLIP	Antibody-based method for locating m <sup>6</sup> A in the whole transcriptome
MeRIP-seq	This method can locate m <sup>6</sup> A residues in the 100-200nt transcription region, and the exact location of m <sup>6</sup> A cannot be identified at the full transcriptome level.

## 1. Components and Recent Advances in Epigenetic Modifications

### 1.1 DNA Methylation

DNA methylation primarily refers to the methylation of the fifth carbon atom of cytosine in CpG dinucleotides, forming 5-methylcytosine (5mC)<sup>[24]</sup>. Two protein families directly participate in DNA methylation pathways: DNA methyltransferases

(DNMTs), which promote and maintain DNA methylation, and the Ten-Eleven Translocation (TET) family proteins, which catalyze multiple steps to remove DNA methylation (Figure 1). Both two families work coordinately to maintain the transcriptional state, exhibiting different site specificity and dependency<sup>[25-27]</sup>. DNMT3A and DNMT3B, aided by DNMT3L, establish de novo DNA methylation<sup>[28]</sup>. Once established, DNA methylation patterns are stably inherited through cell division by DNMT1, endowing DNA methylation with genuine epigenetic modification capabilities<sup>[28,29]</sup>. DNA methylation modulates gene expression primarily by altering DNA accessibility for transcription, leading to downstream recruitment of proteins that regulate chromatin remodeling. On one hand, DNA methylation can obstruct the binding of TFs to promoters<sup>[30]</sup>. On the other hand, TFs can recognize methylated DNA and recruit other TFs to remodel chromatin and initiate transcription<sup>[31]</sup>. Thus, methylated DNA can be recognized by proteins like methyl-CpG binding domain proteins and recruit histone deacetylases (HDACs), thus instigating changes in chromatin structure<sup>[32]</sup>. DNA methylation at CpG islands, particularly in promoters, leads to transcriptional inhibition. One example is high methylation levels support processes like X chromosome inactivation and imprinting<sup>[28,30]</sup>. However, methylation within CpG islands in the gene body is positively correlated with gene expression<sup>[33-35]</sup>. Recently, DNA N6-methyldeoxyadenosine (6mA) within the human genome has come to light<sup>[36,37]</sup>. Numerous studies underscore the unique biological and pathological significance of 6mA in modulating gene transcription, chromatin structure, and disease progression<sup>[38,39]</sup>. Current data suggest a potentially conserved function of 6mA in recognizing and clearing exogenous DNA, thereby participating in immune regulation<sup>[36,38]</sup>.

With the continual advancement in DNA methylation sequencing and molecular biology techniques, our understanding of the functions of DNA methylation is challenging and overturning prior simplistic understandings. Epigenetics mediated by DNA methylation represents a crucial pathway governing the development and activation of the innate immune system. Notably, DNA methylation can undergo rapid changes, especially in response to dynamically shifting environments during

pathogenic infections<sup>[40]</sup>. Remarkably, mounting evidence suggests that pathogens possess the capacity to manipulate DNA methylation or regulate the transcription and activity of DNA methylation-modifying factors like TET and DNMT, leading to transcriptional changes in core gene clusters associated with immune responses<sup>[41-43]</sup>. These shifts in DNA methylation or its modifying agents can play opposite roles, contributing to host immune defense against pathogens or providing pathogens with the means to evade immune responses. Studies indicate that DNA methylation plays a role in regulating monocyte-to-macrophage differentiation, DCs maturation, macrophage polarization, and in controlling T cell differentiation along with memory responses<sup>[15,44-47]</sup>. Consequently, the utilization of candidate genes and epigenome-wide association studies (EWAS) to profile DNA methylation in infected, injured, and immunologically compromised individuals is being employed to elucidate the biological mechanisms underlying disease susceptibility and severity.

## **1.2 Histone Modification**

Histones, a group of alkaline proteins found in the nucleus of eukaryotic cells, bind DNA to form nucleosomes, the fundamental structural units of chromatin<sup>[48]</sup> (Figure 1). Generally, a nucleosome comprises 147 base pairs coiled around an octamer consisting of four pairs of histones (H2A, H2B, H3, and H4). Most histones contain a globular domain and an N-terminal tail protruding outside the nucleosome. Under specific enzymatic action, the amino acid residues in the N-terminal tail covalently attach to corresponding biochemical functional groups such as acetyl, methyl, ubiquitin, etc., leading to subsequent post-translational modifications such as acetylation, methylation, ubiquitination, etc. Notably, covalent modifications of histone N-terminal residues known so far include acetylation, ubiquitination, sumoylation, and biotinylation of lysine; methylation of lysine and arginine; phosphorylation of serine, threonine, and tyrosine, etc. Compared to DNA methylation, histone modifications do not alter the DNA sequence but are more intricate, influencing chromatin structure and transcriptional activity. For instance, histone acetylation serves to diminish the bond strength between histone molecules and DNA or neighboring nucleosomes, relaxing chromatin structure and facilitating

accessibility by TFs and chromatin remodeling factors, thus promoting gene transcription and expression. Hence, histone acetylation is often linked to gene activation<sup>[18,49]</sup>. The role of histone methylation varies, potentially leading to transcription repression or activation based on the placement of amino acid residues on histone N-termini and the quantity of covalently attached methyl groups. For instance, trimethylation of lysine 4 on histone H3 (H3K4me3) activates transcription, while dimethylation of lysine 9 on histone H3 (H3K9me2) suppresses it<sup>[50,51]</sup>. Overall, histone modifications can influence gene expression by altering chromatin structure or recruiting biochemical functional groups. Recently, more and more data suggest the vital importance of histone modifications in gene transcription related to the differentiation and maturation of IIC lineages. These modifications profoundly affect how IICs detect and respond to pathogens, shaping the landscape of associated diseases<sup>[16,52,53]</sup>.

### **1.3 Chromatin Remodeling**

The condensed state of chromatin hinders processes such as gene transcription, DNA replication, and damage repair at the corresponding chromosomal loci. Consequently, eukaryotes have evolved a set of chromatin remodeling enzymes and associated proteins to regulate chromatin structure through modulating nucleosome assembly, disassembly, and rearrangement on chromatin<sup>[54-56]</sup>. One class of proteins involved in this process is the ATP-dependent chromatin remodeling factors (CRCs). These proteins utilize the energy generated by ATP hydrolysis to facilitate the "sliding" of nucleosomes along DNA or mediate the "exchange" between histone variants and canonical histones within the nucleosome. CRCs can be broadly categorized into four major families based on their distinct functional domains: SWI/SNF, ISWI, CHD, and INO80. Despite similarities in protein structure and enzymatic activity among different CRCs, each family exhibits its own specificity. Chromatin remodeling, mediated by CRCs, plays a crucial role in facilitating specific gene transcription, conferring immune cells with the capability to respond to pathogenic infections. For instance, SWI/SNF is involved in chromatin remodeling at the Il-6 gene promoter, thereby promoting Il-6 transcription<sup>[57]</sup>. Furthermore, BRG1,



an ATPase subunit of the SWI/SNF, is indispensable for the transcription of STAT2-dependent pro-inflammatory cytokine genes during TLR4 activation<sup>[58]</sup>.

#### 1.4 RNA m<sup>6</sup>A Methylation

The discovery of RNA m<sup>6</sup>A modification dates back to 1974 in murine Novikoff hepatoma cells<sup>[59]</sup>. However, it wasn't extensively studied until 1997 when Bokar et al. isolated the methyltransferase-like 3 (METTL3) protein from Hela cells<sup>[60]</sup>. RNA m<sup>6</sup>A modification constitutes a dynamic and reversible process that is primarily regulated by three types of enzymes—methyltransferases (writers), demethylases (erasers), and binding proteins (readers)—which collectively modulate post-transcriptional RNA modifications (Figure 1). The demethylation of RNA m<sup>6</sup>A primarily relies on the catalysis of demethylases FTO and  $\alpha$ -ketoglutarate-dependent dioxygenase ALKBH5<sup>[61,62]</sup>. The RNA m<sup>6</sup>A modification is added to RNA by the multi-subunit writers complex consisting of the METTL3-METTL14 heterodimer and numerous additional adaptor proteins. The methyltransferase complex mainly comprises the catalytic subunit METTL3<sup>[63]</sup>, the RNA-binding platform METTL14<sup>[64]</sup>, and the auxiliary factors Wilms tumor-associated protein WTAP and KIAA1429<sup>[65,66]</sup>. The functional effects of m<sup>6</sup>A modification on target RNAs are believed to be mediated by "readers"<sup>[67]</sup>. Among the many "readers," the YTH domain-containing (YTH) protein family has been well studied<sup>[68,69]</sup>, including cytoplasmic members YTHDF1, YTHDF2, and YTHDF3<sup>[70-73]</sup>, as well as nuclear proteins YTHDC1 and YTHDC2<sup>[74,75]</sup>. In addition to YTH family members, other proteins have been identified to recognize and bind to m<sup>6</sup>A. The eukaryotic initiation factor 3 (eIF3) complex interacts with m<sup>6</sup>A-containing 5'UTRs through multi-subunit interfaces, directly recruiting the 40S pre-initiation complex to the 5'UTR of target mRNA to facilitate translation initiation<sup>[76]</sup>. hnRNPA2/B1 and hnRNPG can bind to m<sup>6</sup>A-modified RNAs to regulate splicing and microRNA maturation<sup>[77]</sup>.

RNA m<sup>6</sup>A modification participates in various biological processes. Recent studies demonstrate that RNA m<sup>6</sup>A modification not only engages numerous aspects of RNA metabolism, such as splicing, nuclear export, stability, and translation efficiency<sup>[78]</sup>, but also dynamically regulates gene transcription directly in a

co-transcriptional manner through diverse RNA types, including nascent RNA, long non-coding RNAs (lncRNAs), chromatin-associated regulatory RNAs (carRNAs), endogenous retroviral RNAs (ERVs), and R-loops<sup>[21,79-84]</sup>. On January 31, 2020, the collaborative research team of Chuan He, Dali Han, and Yawei Gao published a groundbreaking study in *Science*, proposing for the first time that m<sup>6</sup>A on carRNA regulates chromatin status and transcription<sup>[84]</sup>. They discovered that carRNA can be methylated by METTL3, resulting in m<sup>6</sup>A modifications. A portion of these m<sup>6</sup>A-modified carRNAs is recognized by YTHDC1 and degraded through the NEXT complex<sup>[84]</sup>. The m<sup>6</sup>A modification serves as a switch that affects the abundance of these carRNAs, thereby regulating the chromatin status and downstream transcription nearby. In addition, the absence of m<sup>6</sup>A leads to the enrichment of certain transcription factors and an increase in active histone markers, inducing transcriptional activation and an increase in chromatin accessibility<sup>[84]</sup>.

The presence of RNA m<sup>6</sup>A modification has been demonstrated to sustain cellular self-recognition of endogenous RNA, while its absence can lead to the generation of aberrant endogenous double-stranded RNA in hematopoietic stem cells (HSCs) and progenitor cells, triggering robust innate immune responses and necrosis within the hematopoietic system<sup>[85]</sup>. The myeloid cell-specific RNA m<sup>6</sup>A modification promotes differentiation of monocytes into macrophages and granulocytes<sup>[86]</sup>, enhancing their capacity to combat pathogen invasion<sup>[87]</sup>. Deletion of METTL14 in macrophages impairs the functionality of CD8<sup>+</sup> T cells<sup>[88]</sup>. In the latter part of this review, we will delve deeper into how RNA m<sup>6</sup>A modification regulates the differentiation and plasticity of IICs.

### **1.5 Non-Coding RNA**

Over 70% of the genetic sequences can be transcribed into RNA, yet only 2% are protein-coding sequences<sup>[89,90]</sup>. ncRNAs are categorized into small miRNAs and long lncRNAs based on their length (Figure 1). miRNAs primarily function as post-transcriptional inhibitors, estimated to regulate over 60% of protein-coding genes. The seed region of miRNA (2-8 nt of the 5' end) guides the RNA-induced silencing complex (RISC) to degrade or inhibit mRNA translation in the ribosome by

complementarily binding to the target gene's mRNA<sup>[91]</sup> (Figure 1). Notably, miRNAs can bind and regulate multiple target genes, modulate various components of the same signaling pathways, and facilitate rapid responses during infections and immune reactions<sup>[18]</sup>. XIST, one lncRNA that drives X chromosome inactivation, was first discovered in 1991<sup>[92]</sup>. With the advancement of sequencing technologies, comprehensive lncRNA profiles in different diseases and cell types have been established, revealing hundreds of disease-regulating lncRNAs. While these lncRNAs have diverse transcription sites, their functions and mechanisms remain similar (Figure 1). For instance, numerous lncRNAs suppress RNA polymerase II or mediate chromatin remodeling and histone modifications, thus influencing downstream gene expression<sup>[18,19]</sup>. Some lncRNAs form RNA-protein complexes with TFs, altering their structure and activity upon binding, thereby regulating gene expression<sup>[20]</sup>. Additionally, lncRNA's self-transcription can interfere with the transcription of neighboring protein-coding genes. Upstream lncRNAs, during transcription, can selectively relocate to the promoter or enhancer regions of nearby genes, occupying the binding sites for TFs and inhibiting gene transcription<sup>[93-95]</sup>. LncRNAs also modulate mRNA expression in various disease microenvironments<sup>[96,97]</sup>. However, only a limited number of lncRNAs are involved in regulating infections and immune responses<sup>[98-100]</sup>. Recent research highlights the indispensable role of lncRNAs in controlling immune cell activation<sup>[101,102]</sup>. A series of lncRNAs such as lincRNA-Cox-2<sup>[103]</sup>, lincRNA-PACER<sup>[104]</sup>, lincRNA-THRIL<sup>[105]</sup>, linc-13<sup>[100]</sup>, lincRNA-EPS<sup>[102]</sup>, lincRNA-ACOD1<sup>[106]</sup>, lincRNA-Mirt2<sup>[107]</sup>, and linc-AAM<sup>[108]</sup> have been reported to regulate macrophage development or activation.




Figure 1. Introduction to epigenetics.

**RNA Methylation.** RNA is transcribed from DNA and subsequently undergoes reversible methylation modifications catalyzed by METTL3/METTL14/WTAP and FTO/ALKBH5. RNA containing m<sup>6</sup>A modifications is recognized by reader proteins, mediating diverse biological functions. **DNA Methylation.** Methylation modifications are written by the DNMTs family on gene promoters, enhancers, and gene bodies. These methylation modifications influence neighboring genes' transcription or chromatin's openness. **ncRNAs.** lncRNAs and miRNAs are transcribed from DNA. lncRNAs, classified according to their transcriptional sites, influence gene transcription, chromatin accessibility, and mRNA stability through various mechanisms. miRNAs primarily affect mRNA cleavage and translation. **Histone Modifications and 3D Chromatin Structure.**

## 2 Epigenetic Modifications Orchestrate Phenotypes of Innate Immune Cells

### 2.1 Epigenetic Modifications Regulate Lineage Development and Polarization of Macrophages

#### 2.1.1 The Role of Epigenetic Modification in Lineage Development of Macrophages

Macrophages serve as the first line of defense against invading pathogens and are pivotal in immune responses. They participate in tissue homeostasis, either facilitating

or resolving inflammation that can lead to tissue damage or contribute to tissue repair. Saeed et al. investigated the epigenetic modifications and transcriptional dynamics during the monocyte-to-macrophage differentiation<sup>[12]</sup> and found that the epigenetic alterations during this process primarily occurred at promoters and distal regulatory elements. Among these, 1240 promoters showed decreased H3K27 acetylation while 1307 promoters exhibited increased H3K27 acetylation<sup>[12]</sup>. This finding suggests a nearly equal number of opened or closed promoter modifications during the monocyte-to-macrophage differentiation process. Further analysis revealed a positive correlation between the existence of H3K27ac elements and the transcriptional activity of adjacent genes<sup>[12]</sup>. Additionally, H3K4me1 was found to provide epigenetic memory during this process<sup>[12]</sup>. These findings suggest a positive correlation between histone H3 modifications (H3K4me3/H3K27ac) at promoters and enhancers' distal regulatory elements (H3K4me1/H3K27ac) during monocyte-to-macrophage differentiation (Figure 2A). Similarly, Dekkers et al. investigated the genome-wide DNA methylation changes during the differentiation of monocytes into macrophages<sup>[15]</sup>. They found that during the differentiation process, there were 4283 upregulated differentially methylated CpGs (DMCs) and 1493 downregulated DMCs. Interestingly, these DNA methylation changes were highly localized, typically affecting individual CpGs that are predominantly within enhancer regions bound by specific TFs (H3K4me1) and in active enhancer regions (H3K4me1/H3K27ac) (Figure 2B). However, this study did not provide sufficient evidence to establish DNA methylation changes as the direct cause driving monocyte differentiation into macrophages. The observed DNA methylation changes might result from downstream impacts of histone modifications or TF binding<sup>[13,14]</sup>. Furthermore, occupancy of TF binding sites by TFs inhibits local DNA methylation, or vice versa. In addition, Rodríguez et al. observed epigenetic dynamic changes during the differentiation of pre-B cells into macrophages<sup>[109]</sup> (Figure 2C). Despite distinct DNA methylation states before and after differentiation were observed, crucial differentiation genes did not exhibit significant changes in DNA methylation. However, C/EBP $\alpha$  was discovered to induce histone modifications in genes associated with macrophage

differentiation, by means of binding to highly methylated promoters of macrophage-specific genes and recruiting p300, a transcriptional co-activator and acetyltransferase. This action activated macrophage-specific gene expression, thereby regulating the differentiation of pre-B cells into macrophages<sup>[109]</sup>. This study emphasizes the role and mechanisms of epigenetic modifications in this reprogramming process, highlighting the importance of epigenetic reprogramming in regulating cell fate transitions.

A report by Sakai focused on the transcriptomic and epigenetic features of newly settled liver macrophages, contributing valuable insights into the mechanisms through which precursor cells develop tissue-specific phenotypes<sup>[110]</sup>. By characterizing the transcriptomic and epigenetic alterations of macrophages resettled in the liver post-acute Kupffer cells (KCs) (liver resident macrophage) depletion, they proposed insights into signaling pathways and TFs that promote KCs differentiation. Post-depletion of KCs, recruited monocytes rapidly differentiated into KCs, and the liver environment reprogrammed the enhancer landscape of the recruited monocytes (Figure 2D). Newly differentiated liver macrophages assumed more accessible chromatin, similar to the observed pattern in KCs. Mechanistic studies revealed that DLL4 activation in sinusoidal endothelial cells triggers the Notch signaling pathway in circulating monocytes. This, in turn, stimulates the expression of KC-specific genes and suppresses the activity of monocyte-specific TFs, thereby giving rise to repopulating liver macrophages (RLMs) (Figure 2D). Subsequently, the Notch signaling pathway and TGF- $\beta$  further activate RLMs at KC-specific gene H3K27ac enhancers, inducing the expression of genes that promote differentiation towards KCs, ultimately leading to the formation of KCs.

Taken together, these findings collectively suggest that ecological signals under physiological and pathological environments have the capability to induce specific differentiation or phenotypic transitions in tissue-resident macrophages, precursor cells, and monocytes by reconfiguring their epigenomes.






Figure 2. The role of epigenetic modification in lineage development of macrophages. A. The role of H3K27ac and H3K4me3 in guiding monocyte-to-macrophage differentiation. B. Increased DNA methylation during monocyte-to-macrophage differentiation promotes the binding of transcription factors and active histone elements to relevant differentiation genes. C. Epigenetic patterns during pre-B cell-to-macrophage differentiation. D. Epigenetic characteristics and mechanisms underlying the differentiation of newly settled hepatic macrophages.

### 2.1.2 The Role of Epigenetic Modification in Macrophages Polarization

Macrophages exhibit remarkable heterogeneity and plasticity, with their phenotype and function regulated by the surrounding environment, a process referred to as macrophage polarization<sup>[111,112]</sup>. Typically, macrophages sense and engulf the host, presenting fragmented peptides to helper T cells (Th) when pathogens invade the host. Simultaneously, macrophages release pro-inflammatory cytokines and chemokines to eradicate the pathogens, while simultaneously secreting

anti-inflammatory cytokines and chemokines to protect the organism. Two discernible polarization states are observed in macrophages: M1, which releases pro-inflammatory cytokines, represents the classically activated macrophages, while M2, releasing anti-inflammatory cytokines, represents alternatively activated macrophages<sup>[113-115]</sup>. Upon exposure to pathogenic inflammatory stimuli, gene transcription in macrophages undergoes significant changes, leading to the activation of macrophages (Figure 3). Activation enables them to respond to infection and stimuli more effectively, thus establishing immune homeostasis. However, if the transcriptional pattern activated by inflammation persists, macrophages can become excessively activated, thereby compromising host health<sup>[116]</sup>. Substantial evidence suggests macrophage polarization is a reversible and adjustable dynamic process that participates in numerous immune-inflammatory diseases' onset, progression, and outcomes. Consequently, macrophages have emerged as attractive therapeutic targets and research focal points in recent years. The 'reprogramming' of macrophage states represents a promising new therapeutic strategy.






Figure 3: Epigenetic Modifications and Macrophage Polarization.

DNMT1- and DNMT3b-mediated DNA methylation favors M1 macrophage polarization, whereas DNMTs inhibitors-induced DNA demethylation typically promotes M2 macrophage polarization. HDAC3-mediated histone deacetylation commonly enhances M1 macrophage polarization, whereas HDAC1 and HDAC10-mediated histone deacetylation typically favors M2 macrophage polarization. SETDB1-mediated H3K9 methylation and KDM5B-mediated H3K4 methylation often promote M1 macrophage polarization, while JMJD3 and KDM6A-mediated H3K27 demethylation typically favors M2 macrophage polarization. METTL3/METTL14 and YTHDF1-mediated RNA m6A modification contributes to M1 macrophage polarization. Lnc-AAM, LncRNA-GAS5, and LncRNA-CCL2 enhance M1 macrophage polarization, while LncRNA-Dnmt3aos,

LncRNA-AK085865, and LncRNA-NEAT1 promote M2 macrophage polarization.

### **2.1.2.1 DNA Methylation Modulates Macrophage Polarization**

DNA methylation has been demonstrated to modulate gene transcription in macrophages in responding to the pathogenic mechanisms of various diseases including inflammation<sup>[46]</sup>. Jain et al. found that during LPS-induced polarization of macrophages towards the M1 phenotype, there was an overall decrease in 5mC levels, along with an increase of non-methylated CpG sites, suggesting a notable reduction in DNA methylation associated with macrophage M1 polarization<sup>[45]</sup>. DNMT3a-mediated Pstpip2 methylation enhances macrophage activation and inflammation in liver injury by modulating the STAT1 and NF- $\kappa$ B pathways<sup>[117]</sup>. Additionally, studies indicate that DNMT3b also regulates macrophage polarization and inflammation. Elevated levels of DNMT3b, associated with pro-inflammatory M1 macrophages, were observed in obese mice; knocking out DNMT3b promoted macrophage polarization toward an alternative M2 state<sup>[118]</sup>. The methylation of the TNF- $\alpha$  gene, mediated by Uhrf1, controls pro-inflammatory macrophage polarization in experimental colitis models, resembling inflammatory bowel disease<sup>[119]</sup>. Promoting macrophage M2 polarization can be facilitated by inhibiting DNA methylation at the PPAR $\gamma$ 1 promoter using 5-azacytidine (DNMT inhibitor) or through DNMT1 deficiency<sup>[120,121]</sup>. These instances provide explicit evidence that inhibiting DNA methyltransferases can facilitate the transcriptional activation of M2 macrophage-associated genes. Inhibitors targeting DNMTs may enhance anti-inflammatory responses, thus alleviating damage.

### **2.1.2.2 Histone Modification Regulates Macrophage Polarization**

Epigenetic modifiers such as histone methyltransferases and acetyltransferases exhibit differential expression in macrophage M1/M2 states, suggesting they play a role in maintaining and regulating macrophage M1/M2 polarization<sup>[122]</sup>. For instance, HDAC10 is upregulated in macrophages and the upregulation promotes activation of mouse M2 macrophages<sup>[123]</sup>. Inhibiting HDAC6 and HDAC8 suppresses macrophage M2 polarization<sup>[124-126]</sup>. Moreover, inhibition of HDAC6 and HDAC3 substantially suppresses LPS-induced macrophage M1 polarization and reduces pro-inflammatory

cytokine production<sup>[127]</sup>. Epigenetic regulation by H3K4 and H3K27 methylation influences M2 macrophage polarization genes. For instance, the STAT6-dependent induction of JMJD3, an H3K27 demethylase, reduces H3K27 methylation in the promoter regions of genes associated with M2 macrophage polarization, thus maintaining their transcriptional activity<sup>[128]</sup>. Histone H3K27 demethylase KDM6A-dependent demethylation regulates *Ire1 $\alpha$*  expression, which enhances M2 macrophage polarization<sup>[129]</sup>. Histone demethylase JMJD1C upregulates miR-302a to promote M1 macrophage polarization<sup>[130]</sup>. Knockout of *Setdb1*, a macrophage-specific H3K9 methyltransferase, in mice upregulated IL-6 levels upon LPS stimulation and increased its susceptibility to endotoxic shock, indicating that H3K9 methyltransferase SETBD1 is an epigenetic regulator of pro-inflammatory cytokine expression<sup>[131]</sup>. Genome-wide analysis of KDM5B binding peaks revealed its selective recruitment to the *Nfkbia* gene promoter, associated with activated macrophages. KDM5B-mediated erasure of H3K4me3 reduces chromatin accessibility at the *Nfkbia* gene locus, resulting in reduced *I $\kappa$ B $\alpha$*  expression and augmented macrophage activation mediated by NF- $\kappa$ B pathway<sup>[132]</sup>. Additionally, Ornithine Decarboxylase (ODC) deficiency during bacterial infection mitigates H3K9 methylation to enhance M1 macrophage polarization<sup>[133]</sup>.

During LPS-induced M1 macrophage polarization, HDAC3 interacts with activating TF to facilitate transcriptional activation in an enzymatic-independent manner<sup>[134]</sup>. This suggests HDAC3 not only regulates chromatin activity through histone deacetylation but also modulates gene transcription through interacting with key macrophage TFs. Arginine methyltransferase 1 (PRMT1) regulates c-Myc-dependent transcription by altering acetyltransferase p300 recruitment to its promoter. PRMT1 inhibition decreases p300 recruitment to c-Myc target promoters, and increases HDAC1 recruitment, thereby reducing transcription at these sites. Inhibiting PRMT1 disrupts induction of several c-Myc-mediated target genes, including PPAR $\gamma$  and MRC1, highlighting the necessity of PRMT1 in c-Myc function during M2 macrophage differentiation<sup>[135]</sup>. These data indicate that various chromatin-modifying factors may interact with same TFs to regulate distinct gene

subgroups. In conclusion, the relationship between histone modifications and macrophage polarization is crucial for understanding macrophages' heterogeneity and functional transition.

### **2.1.2.3 RNA m<sup>6</sup>A Methylation Regulates Macrophage Polarization**

In the past five years, extensive evidence confirmed that RNA methylation plays a crucial role in transcription initiation, regulation of nascent RNA transcription and chromatin-associated RNA m<sup>6</sup>A methylation, consequently regulating chromatin openness and activity during the development and differentiation of embryonic HSCs. However, the specific impact of RNA methylation in monocyte-to-macrophage differentiation and M0 to M1/M2 polarization remains unclear. Through transcriptomic analysis of nascent RNA, m<sup>6</sup>A methylation profiling, and chromatin accessibility sequencing, we found that METTL3 regulates m<sup>6</sup>A modification and transcription of nascent RNA and chromatin-enriched non-coding RNAs (caRNAs) during macrophages polarization from M0 to M1 polarization. The loss of METTL3 significantly reverses the expression of nearly 40% of genes involved in M0 to M1 polarization, including the NF-Kb and JAK-STAT signaling pathways. This suggests that RNA m<sup>6</sup>A methylation modulates the global dynamic transcription and chromatin accessibility during the macrophage transition from M0 to M1, thereby imparting plasticity to macrophages (unpublished data).

In addition, extensive research highlighted the impact of RNA m<sup>6</sup>A methylation on the stability and translation efficiency of mRNAs that are related to macrophage polarization, thereby mediating the activation of crucial pathways involved in this process. For instance, Qin and colleagues revealed that conditional METTL3 knockout in myeloid cells inhibits liver macrophage as well as T-cell differentiation. This can be attributed to the absence of METTL3 in macrophages, which leads to low levels of Ddit4 mRNA m<sup>6</sup>A modification and enhanced stability. Ddit4 subsequently suppresses mTOR and NF-κB signaling pathways mediating macrophage activation and inflammatory responses<sup>[136]</sup>. Moreover, Tong et al. established a CRISPR screening system to induce M1 polarization in LPS-stimulated macrophages, revealing METTL3 as a critical factor in macrophage activation based on differential

TNF- $\alpha$  expression. Mechanistically, METTL3 promotes Irakm mRNA m<sup>6</sup>A modification and its degradation, leading to Irakm-TLR signaling activation and macrophage M1 polarization<sup>[87]</sup>. Furthermore, research elucidated that METTL3 directly methylates STAT1 mRNA, thus enhancing its stability and STAT1 expression. STAT1 next binds to the promoters of pro-inflammatory genes to promote polarization towards M1 and inhibit M0 to M2 polarization<sup>[137,138]</sup>. The METTL3-driven m<sup>6</sup>A function also stimulates the development of miR-34a-5p which, by interacting with Sirt1 mRNA in KCs to suppress its translation, affects the transcription and translation of certain genes associated with M1 polarization<sup>[139]</sup>. Additionally, Han and colleagues demonstrated that the knockout of METTL3 in myeloid cells intensifies Th2 cell responses and exacerbates allergic airway inflammation by activating M2 macrophage. Mechanistically, METTL3 facilitates m<sup>6</sup>A modification of PTX3 mRNA to promote its YTHDF3-dependent degradation, resulting in reduced PTX3 levels. The decreased PTX3 suppresses macrophage M2 polarization, thereby promoting allergic airway inflammation<sup>[140]</sup>. These studies collectively emphasize the contribution of METTL3 to promoting macrophage transition from M0 to M1.

Similar to METTL3, METTL14 was also found to facilitate M0 to M1 polarization while inhibiting M0 to M2 polarization. For example, Zheng and colleagues found that METTL14, through m<sup>6</sup>A modification, enhances Myd88 mRNA stability, consequently promoting Myd88-p65 axis-mediated IL-6 transcription<sup>[141]</sup>. This process facilitates macrophage M0 to M1 polarization while suppressing M2 polarization, thus promoting foam cell formation and enhancing migration<sup>[141]</sup>. Additionally, research has indicated that METTL14, through the KAT3B-STING axis, regulates M1 polarization and triggers NLRP3 inflammasome activation in macrophages post-ischemic stroke<sup>[142]</sup>. Conversely, Wang et al. found a negative regulation of macrophage M1 polarization by METTL14. They observed that LPS-induced KAT2B-mediated acetylation of METTL14 at the K398 site enhances the stability of METTL14 protein, which next promotes m<sup>6</sup>A modification of Spi2a mRNA via the YTHDF1 axis. Elevated SPI2A binds to IKK $\beta$  to inhibit NF- $\kappa$ B pathway, thus inhibiting macrophage M1 polarization<sup>[143]</sup>. Similarly, Du et al.

identified METTL14-mediated m<sup>6</sup>A modification on Socs1 mRNA enhances YTHDF1 translation, which eventually inhibits TLR4/NF-κB signal transduction and macrophage M1 polarization<sup>[144]</sup>. Reintroducing SOCS1 in METTL14 or YTHDF1-deficient macrophages rescued their heightened inflammatory phenotype<sup>[144]</sup>. Moreover, conditional loss of METTL14 in myeloid cells exacerbated macrophages' reaction to acute bacterial infection in mice, resulting in higher mortality rates<sup>[144]</sup>. These findings indicate that m<sup>6</sup>A-mediated expression of Socs1 maintains a negative feedback loop that regulates macrophage activation during bacterial infections.

The RNA demethylase FTO has been discovered to promote both M1 and M2 polarization. This occurs through selective removal of m<sup>6</sup>A modifications from Stat1 and Ppar-γ mRNA, thus inhibiting YTHDF2-mediated degradation of Stat1 and Ppar-γ mRNA and hindering macrophage activation<sup>[145]</sup>. Additionally, the RNA demethylase ALKBH5 diminishes the m<sup>6</sup>A modification on Cdca4 mRNA which leads to the reduced binding of YTHDC2 to its m<sup>6</sup>A site to inhibit YTHDC2-mediated degradation. The elevated CDCA4 promotes macrophage M2 polarization<sup>[146]</sup>. It has also been reported that the absence of YTHDF2 in macrophages suppresses macrophage M2 polarization by m<sup>6</sup>A-mediated degradation of Hmox1 mRNA. The lower level of HMOX1 facilitates the release of inflammatory factors<sup>[147]</sup>. Furthermore, Huangfu et al. discovered the interaction between RBM4 and YTHDF2, which leads to the degradation of m<sup>6</sup>A-modified Stat1 mRNA and subsequently regulates IFN-γ-induced M1 polarization<sup>[148]</sup>.

The cumulative findings emphasize the crucial role of RNA m<sup>6</sup>A in the development and polarization of macrophage lineages. It is evident that an increase in METTL3 or METTL14-mediated RNA m<sup>6</sup>A methylation is recognized by YTHDF1 or YTHDF2, which subsequently promotes M1 macrophage polarization. Conversely, RNA m<sup>6</sup>A demethylation mediated by FTO or ALKBH5 typically favors M2 macrophage polarization. Therefore, unraveling the underlying molecular mechanisms and identifying key regulatory elements or genes mediated by m<sup>6</sup>A modifications will aid in designing and developing small molecule inhibitors or activators targeting RNA



m<sup>6</sup>A methylation enzymes or critical genes' m<sup>6</sup>A modifications involved in the development and polarization of macrophage lineages, ultimately providing potential therapies for mitigating inflammation resulting from macrophage polarization.

#### **2.1.2.4 Regulation of Macrophage Polarization by Non-Coding RNAs**

lncRNAs play a pivotal role in the specific regulation of macrophage polarization through various mechanisms, mediating the onset and progression of various diseases. Ma et al. reported altered expression of snRNAs during macrophage polarization, showing differences in the expression of hundreds of ncRNAs during M1 polarization of macrophages<sup>[149]</sup>. The roles and mechanisms of some ncRNAs in regulating macrophage polarization have been elucidated. For instance, linc-AAM is induced early in macrophage activation, and its subsequent upregulation promotes the transcription of a series of immune response genes (IRGs), further fostering macrophage activation<sup>[108]</sup>. linc-AAM can selectively recognize the promoter sequences of IRGs. Simultaneously, the linc-AAM sequence encompasses two CACACA motifs recognized by heterogeneous nuclear ribonucleoprotein L (hnRNPL). Once interaction occurs between the two, it leads to the dissociation of hnRNPL from the hnRNPL-H3 complex, thus fostering chromatin accessibility and promoting IRG transcription<sup>[108]</sup>. It is noteworthy that the knockout of linc-AAM in mice exhibited compromised antigen-specific cellular and humoral immune responses<sup>[108]</sup>, suggesting that linc-AAM-mediated macrophage activation supports the establishment of adaptive immunity. LncRNA-GAS5 overexpression *in vitro* upregulates STAT1, promoting macrophage polarization toward the M1 phenotype<sup>[150]</sup>. LncRNA-MM2P inhibits M1-polarized macrophages' excessive inflammation by interfering with SHP2-mediated STAT3 dephosphorylation<sup>[151]</sup>. LncRNA-CCL2 regulates the expression of inflammatory cytokines in macrophages during sepsis<sup>[152]</sup>. Li et al. discovered numerous lncRNAs with differential expression in macrophages before and after polarization, among which lncRNA-Dnmt3aos is positioned on the antisense strand of Dnmt3a. Functional experiments further confirm that lncRNA-Dnmt3aos promotes M2 macrophage polarization by regulating downstream Dnmt3a gene expression<sup>[153]</sup>. LncRNA-AK085865 is markedly expressed in allergic

asthma mice and drives macrophage polarization towards M2; its depletion reduces M2 macrophage polarization, suggesting that silencing lncRNA-AK085865 could ameliorate allergic asthma airway inflammation by modulating macrophage polarization<sup>[154]</sup>. LncRNA-NEAT1 enhances B7-H3 expression and JAK2-STAT3 signaling activation by downregulating miR-214, promoting M2 macrophage polarization<sup>[155]</sup>. Additionally, miR-30b-5p releases HMGB1 through the UBE2D2/KAT2B/HMGB1 pathway, promoting pro-inflammatory polarization and macrophage recruitment<sup>[156]</sup>.

## **2.2 Epigenetic Modifications Modulate Differentiation and Maturation of Dendritic Cells**

In the bone marrow, HSCs generate multipotent progenitors (MPPs), which can further differentiate into common myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs). CMPs expressing Flt3 differentiate into macrophage-dendritic cell progenitors (MDPs)<sup>[157-159]</sup>. Common DC progenitors (CDPs) derived from MDPs can differentiate into conventional dendritic cell precursors (pre-cDCs) and plasmacytoid DC precursors (pre-pDCs)<sup>[159,160]</sup>. Pre-cDCs move from the bone marrow into the bloodstream and migrate to lymphoid and non-lymphoid organs, differentiating into cDCs. As MPPs differentiate into CDPs, the genetic profile for classical DCs (cDCs) and plasmacytoid DCs (pDCs) undergoes epigenetic activation and loss of inhibitory histone marks<sup>[161]</sup>. The process from HSCs differentiation to mature DCs (mDCs) encompasses several intermediate stages, with each stage gradually limiting their developmental and differentiation potential. This suggests that gene expression patterns encounter increasing constraints during lineage cell differentiation. However, existing research indicates that epigenetics participates in reshaping chromatin structure, thereby influencing the transition of gene expression patterns during lineage cell differentiation<sup>[162]</sup>.

### **2.2.1 Epigenetic Modification Influences the Differentiation and Maturation of Dendritic Cells by Regulating the Expression and Function of Key Transcription Factors**

Vento et al. compared the DNA methylation dynamics in the differentiation



process of monocytes into DCs and macrophages, identifying distinct gene sets experiencing DC-specific or macrophage-specific demethylation. Their findings indicated the role of IL-4 in coordinating STAT6-mediated DNA demethylation, crucial for monocyte differentiation into DCs<sup>[163]</sup>. Pu.1, as a TF, holds a pivotal role in hematopoiesis and exhibits continuous expression along the lineage of DCs. Loss of the histone deubiquitinase MYSM1 impairs DCs development without affecting other myeloid cell lineages, including monocytes, macrophages, and granulocytes. Mechanistic studies revealed that MYSM1 regulates Flt3 transcription by controlling histone modifications and Pu.1 recruitment, thereby controlling the differentiation of DCs and CMPs<sup>[164]</sup>. To unravel the functional roles of lncRNAs in human DCs, Wang et al. employed lncRNA gene chip analysis to examine the expression profile of lncRNAs in monocyte-derived DCs and LPS-induced mDCs from peripheral blood. They discovered the significantly elevated expression of linc-DC (>100-fold) specifically in mDCs. Mechanistic insights revealed that during the maturation of DCs, the genomic regions of linc-DC gradually acquired an open and accessible chromatin structure favoring H3K4me3 and H3K27ac levels, thereby facilitating the binding of the TF PU.1, ultimately resulting in the production of linc-DC in mDCs. The transcribed linc-DC directly binds to the structural region near the phosphorylation site Tyr705 of STAT3, inhibiting SHP1-mediated dephosphorylation and enhancing STAT3 signaling, thereby promoting DC maturation and maintaining DC functionality<sup>[101]</sup>. Pacis et al. comprehensively reported the DNA methylation profile of monocyte-derived DCs for the first time. They found extensive and rapid loss of DNA methylation during *Mycobacterium tuberculosis* (MTB) infection in human DCs<sup>[41]</sup>, a process dependent on TET2<sup>[41,163]</sup>. However, the understanding of how DNA methylation regulates the development from CMPs to DCs and the DNA methylation patterns during the gradual differentiation of DCs from HSCs remains limited. Nevertheless, studies have indicated that Pu.1 can recruit TET2 and DNMT3b to target genes, as observed during osteoclast differentiation from monocytes<sup>[13]</sup>. Based on this, it can be speculated that in the development of DCs, Pu.1 might interact with TET and DNMT, inducing DNA methylation of certain regulatory

differentiation genes. These interactions can then lead to the recruitment of chromatin-modifying factors, including histone modifiers, to regulate the chromatin state at these genes. This regulation of the chromatin state ultimately affects the transcription of the differentiation genes, promoting their activation or silencing, which is crucial for the proper development and differentiation of DCs.

Irf8 serves as a decisive factor in the development of the DC lineage. It initiates the differentiation of HST and MPP into DCs, and its deficiency inhibits the transition of MDP into CDP<sup>[165-168]</sup>. Xu et al. identified a novel lncRNA termed lncIrf8, which is transcribed from the downstream +32 kb enhancer of the Irf8 locus and exhibits specific expression in pDCs, while it remains unexpressed in MPPs, CDPs, cDC1s, and cDC2s. lncIrf8 binds to the Irf8 promoter and demonstrates distinct epigenetic characteristics in pDCs compared to cDC1s. Elimination of the lncIrf8 promoter impairs the development of both pDCs and cDC1s, while leaving cDC2s unaffected. However, activating the lncIrf8 promoter notably enhances cDC1s development. In cDC1s, the +32 kb enhancer negatively regulates the IRF8-repressive protein complex, thereby restricting the auto-activation and expression of Irf8. Conversely, in pDCs, there is relatively less binding between the IRF8-repressive protein complex and the +32 kb enhancer, resulting in heightened transcription of Irf8 and lncIrf8<sup>[169]</sup>.

### **2.2.2 Histone Modification Modulates Differentiation and Maturation of Dendritic Cells**

In recent years, scientists have gradually unraveled the roles of various epigenetic modifier enzymes in DC lineage development and activation by generating mice or cells with specific deletions in distinct epigenetic modifications<sup>[170]</sup>. For example, Zhang and colleagues discovered the heightened level of HDAC3 in pDCs, and its deficiency significantly impairs pDC development. Mechanistically, the lack of HDAC3 results in a considerable decline in the gene transcriptions related to pDC differentiation, while genes linked to cDC differentiation are notably upregulated, consequently leading to a significant reduction in CDP's ability to differentiate into pDCs. This is due to the significant increase in H3K27ac, mediated by HDAC3 knockout, at critical genes for pDC differentiation such as Zfp366, Zbtb46, and Batf3,

thereby regulating gene expression levels and the development and differentiation of the DC lineage<sup>[171]</sup>. Moreover, during monocyte-to-DC differentiation, HDAC4 recruitment to the Arg1 promoter region is enhanced, leading to reduced H3 and STAT6 acetylation. This reduction promotes STAT6 binding to the Arg1 promoter and activation of Arg1 transcription, further enhancing the expression of Arg1 and facilitating DC differentiation<sup>[172]</sup>. PCGF6 serves as a member of the Polycomb group involved in epigenetic regulation. PCGF6 expression is observed in resting-state DCs and is downregulated following DC activation. Furthermore, HDACs mediate STAT3 deacetylation, also contributing to monocyte-to-DC differentiation<sup>[173]</sup>. Boukhaled et al. identified that PCGF6 interacts with the H3K4me3 demethylase JARID1c, jointly negatively regulating H3K4me3 modification in DCs, thereby impacting the chromatin accessibility of critical genes crucial for DC activation<sup>[174]</sup>. These findings suggest that HDACs and histone demethylases, among others, exert control over the fate transition of DCs by modulating chromatin modifications at key gene loci or modifying their TFs during DC maturation and differentiation.

### **2.2.3 RNA m<sup>6</sup>A Methylation Regulates Differentiation and Maturation of Dendritic Cells**

In recent years, research into the involvement of RNA m<sup>6</sup>A methylation in regulating DC development and activation has emerged. Yin et al. systematically profiled 16 different HSCs, progenitors, and mature blood cells in the murine hematopoietic system, including MPP, CMP, GMP, MDP, and DC. They observed a higher m<sup>6</sup>A modification level in long-term HSCs, which subsequently declined as they differentiated into myeloid and erythroid lineages, while the lymphoid cell population exhibited elevated RNA m<sup>6</sup>A modifications<sup>[175]</sup>. This observation suggests that RNA m<sup>6</sup>A methylation negatively regulates the differentiation of HSCs into myeloid cells and DCs. However, during the maturation process within the DC lineage, Wang and colleagues discovered that METTL3-mediated m<sup>6</sup>A modifications on transcripts such as Cd40, Cd80, TlrR4, and Tirap enhanced their recognition by YTHDF1, promoting their translation in DCs. This facilitated DC maturation and activation, thereby strengthening cytokine production induced by TLR4/NF-κB

signaling<sup>[176]</sup>. This indicates a positive regulatory impact of RNA m<sup>6</sup>A methylation in the maturation and activation of DCs. Further research by Bai et al. revealed that the loss of the RNA m<sup>6</sup>A reader protein YTHDF1 led to heightened recruitment of mDCs, elevated MHCII, as well as enhanced secretion of IL-12<sup>[177]</sup>. Consequently, this promoted infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, boosting IFN- $\gamma$  secretion, and thereby contributing to alleviating disease. Thus, RNA m<sup>6</sup>A methylation plays a role in modulating DCs during immune responses.

### **2.2.3 Non-Coding RNA Modulates Differentiation and Maturation of Dendritic Cells**

In addition to the aforementioned lncIrf8 and lnc-dc, numerous lncRNAs also participate in regulating the differentiation and maturation of DCs. For instance, lncRNA-MIR155HG can modulate the immune function of DCs by impacting HSC differentiation<sup>[178]</sup>. Moreover, lncRNA-HOTAIRM1 inhibits monocytic differentiation into DCs by targeting the miR-3960/HOXA1 pathway<sup>[179]</sup>. HOXA1 serves as a differentiation inhibitory molecule for DCs. The interaction between lncRNA-HOTAIRM1 and miR-3960 promotes HOXA1 expression, leading to the upregulation of monocytic markers CD14 and B7H2, ultimately maintaining the monocytic phenotype and suppressing their differentiation into DCs. Thus, lncRNA-HOTAIRM1, miR-3960, and HOXA1 form a competitive endogenous RNA network, exerting regulatory roles during DC lineage development<sup>[179]</sup>. The migration of leukocytes is controlled by interactions between chemokines and their receptors, determining the characteristics and consequences of immune responses driven by DCs<sup>[180-182]</sup>. pDCs mature in response to microbial products or inflammatory signals, subsequently upregulating CCR7. CCL21 and CCL19 act as ligands for CCR7, regulating the drainage of DCs to lymph nodes to induce adaptive immunity<sup>[183-185]</sup>. Abnormal DCs transport and aggregation are associated with the pathogenesis of diverse inflammatory conditions<sup>[186]</sup>. Research indicates that the chemokine receptor CCR7 expressed by DCs negatively regulates DC migration by inhibiting m<sup>6</sup>A modifications on lnc-Dpf3 within DCs, leading to increased lnc-Dpf3 expression and thereby suppressing the occurrence and progression of inflammatory diseases<sup>[187]</sup>.

## **2.2.4 Discussion on the Roles of Epigenetic Modifications on Differentiation and Maturation of Dendritic Cells**

The regulatory networks and mechanisms governing the plasticity of epigenetic control in the development and phenotypic characteristics of DC subsets have not been as clearly elucidated as in macrophage studies. Many questions remain unanswered in this regard. For instance, how signals from disease and the local microenvironment are transmitted to the epigenetic modifiers and chromatin during the differentiation phases of subsets like MPP, MDP, cDCs, or pDCs, especially during pathogen infections. Furthermore, how chromatin and epigenetic information reciprocally regulate their differentiation, migration, and activation in DCs. Another consideration is whether the differences in the epigenetic landscape of DCs directly reflect the phenotype, function, and activation status of DC subsets.

## **2.3 Epigenetic Modifications Modulate Lineage Development and Activation of Innate Lymphoid Cells**

In terms of function and development, ILCs resemble T cells but lack adaptive antigen receptors. ILCs primarily consist of ILC1s, ILC2s, ILC3s, and natural killer (NK) cells. Through the expression of various integrins, chemokine receptors, and cytokine receptors, ILCs rapidly sense environmental changes, enabling them to swiftly secrete potent cytokines to combat infections and tissue remodeling<sup>[188,189]</sup>. The lineage development, differentiation, and maturation of ILCs are also regulated, which depends on specific TFs and epigenetic mechanisms, with the expression of particular TFs also relying on the involvement of multiple epigenetic modifications<sup>[1,190,191]</sup>.

### **2.3.1 Epigenetic Modifications Regulates Lineage Development and Activation of ILC1s, ILC2s and ILC3s**

#### **2.3.1.1 Epigenetic Modification Influences Lineage Development and Activation of ILC1s, ILC2s and ILC3s by Mediating the Expression and Function of Key Transcription Factors**

The ILCs lineage is determined by ID2, a TF that counters the specific gene transcription in T and B cells. Typically, the Id2 gene remains suppressed, awaiting

future activation<sup>[192,193]</sup>. Michieletto et al. conducted a comprehensive analysis of mature ILCs' three-dimensional genome structure, chromatin accessibility, and gene expression, revealing the mechanism by which ILC2s specifically activate through dynamic reshaping of the Id2 gene locus's three-dimensional structure during early development<sup>[192]</sup>. Their study found that the local three-dimensional structure of the genome is selectively reconnected at sites relevant to ILCs function, facilitating the lineage development and functional differentiation of ILCs. Moreover, multiple interactions between Id2 gene locus and distal cis-regulatory elements bound by ILC2s-associated TFs GATA3 and ROR $\alpha$  shape a unique local 3D structure, thereby promoting the development of ILC2s and allergic airway inflammation. Additionally, Mowel et al. discovered that lncRNA-Rroid in ILC1s interacts with the promoter sequence of the adjacent Id2. It is the gene locus of lncRNA-Rroid, rather than the molecule itself, that responds to IL-15 by enhancing chromatin accessibility and facilitating STAT5 deposition in the Id2 promoter, thereby governing the differentiation and function of ILC1s. Moreover, lncRNA-Rroid is also indispensable for the early development and homeostasis of ILC2s and ILC3s<sup>[194]</sup>.

### **2.3.1.2 Non-Coding RNA Modulates the Lineage Development and Activation of ILC1s, ILC2s and ILC3s**

Numerous ncRNAs participate in regulating ILCs lineage development. For instance, Liu et al. found high expression of lncRNA-Kdm2b expression in ILC3s. Lacking lncRNA-Kdm2b in the hematopoietic system results in reduced numbers and effector functions of ILC3s. This is because lncRNA-Kdm2b promotes the proliferation of ILC3s through activating the TF ZFP292, thereby sustaining ILC3s maintenance. Mechanistically, lncRNA-Kdm2b recruits some CRCs to the Zfp292 promoter to drive its transcription. The lack of ZFP292 disrupts ILC3 maintenance, increasing susceptibility to bacterial infections<sup>[195]</sup>. Furthermore, the circular RNA circTmem241 exhibits high expression in ILC3 and its progenitor cells<sup>[196]</sup>. Its depletion impairs the function of ILC3 and inhibits antibacterial immunity. Within ILC precursors (ILCPs), circTmem241 interacts with the NONO protein, recruiting the histone methyltransferase ASH11 to the Elk3 promoter. At the Elk3 promoter, ASH11

facilitates H3K4me3 and H3K36me3, thereby heightening chromatin accessibility and initiating Elk3 transcription. Conditional gene editing experiments in ILCPs mice indicated a substantial disruption in the differentiation capability of ILC3s and increased susceptibility to bacterial infections upon the loss of circTmem241, Nono, or Ash11. Conversely, overexpression of Elk3 in mice with ILCPs-specific deficiencies in circTmem241, Nono, or Ash1 defects restored the differentiation ability of ILC3s and enhanced their resistance to infections. This suggests that the circTmem241-Nono-Ash1-Elk3 axis emerges as pivotal in steering ILCPs towards mature ILC3s, highlighting the axis' critical regulatory potential in therapeutic strategies targeting infectious diseases<sup>[196]</sup>. Moreover, circular RNAs also interact with RNA m<sup>6</sup>A modifications to regulate ILC3 development. Liu et al. discovered the high expression of the circular RNA circZbtb20 in ILC3. The lack of circZbtb20 diminishes ILC3 numbers and increases susceptibility to *Citrobacter rodentium* infection. Mechanistically, the 1200-1605 region of circZbtb20 interacts directly with ALKBH5. Subsequently, ALKBH5 removes the m<sup>6</sup>A on Nr4a1 mRNA, which enhances the stability of Nr4a1 mRNA. Subsequently, NR4A1 activates the Notch2 signal to maintain ILC3 homeostasis. Meanwhile, mice with the lack of Alkbh5 or NR4A1 disrupt ILC3s lineage development and intestinal immune homeostasis, rendering them more susceptible to *Citrobacter rodentium* infection<sup>[197]</sup>. This further corroborates the role of circZbtb20-Alkbh5-Nr4a1 axis in regulating the development and maturation of ILC3.

### **2.3.1.3 RNA m<sup>6</sup>A Methylation Modulates the Lineage Development and Activation of ILC1s, ILC2s and ILC3s**

Additionally, RNA m<sup>6</sup>A methylation participates in regulating ILCs lineage development. Zhang et al. observed that the absence of METTL3 had minimal impact on the homeostasis of ILC or the cytokine-induced responses of ILC1 or ILC3. However, it significantly reduced the proliferation, migration, and effector cytokine production of ILC2, leading to compromised immune function. Mechanistic studies revealed that METTL3 facilitated the high methylation of Gata3 mRNA in ILC2s, thereby enhancing Gata3 mRNA stability to promote ILC2 activation<sup>[198]</sup>. GATA3



stands as an essential TF for the development of all ILCs<sup>[199]</sup>.

#### **2.3.1.4 Histone Modification Regulates the Lineage Development and Activation of ILC1s, ILC2s and ILC3s**

Histone acetylation and methylation have also been found to participate in regulating the activation of ILCs. During the multipotent hematopoietic stem cell stage, HDAC3 promotes the normal differentiation of immune cells by maintaining chromatin structure and genomic stability. The absence of HDAC3 at this stage prevents lymphoid progenitors from efficient DNA replication, leading to cell cycle S-phase arrest and ultimately diminishing the development and differentiation of ILCs<sup>[200]</sup>. Toki and colleagues discovered that Trichostatin A (TSA), an inhibitor of HDACs, reduced allergen-induced ILC2s activation and the early innate immune response to inhaled protease-containing airborne allergens<sup>[201]</sup>. The BET bromodomain is an evolutionarily conserved protein domain capable of recognizing and binding acetylated lysine residues on histones. Its inhibitor, iBET151, effectively hinders human ILC2 activation and suppresses type 2 immune responses<sup>[202]</sup>. Antignano et al. identified the role of lysine methyltransferase G9a in regulating ILC2s development and function<sup>[203]</sup>. They found that hematopoietic cell-specific G9a deficiency led to a drastic reduction in peripheral ILC2s. Mechanistic studies revealed that H3K9me2 mediated by G9a is necessary for silencing ILC3s-related genes in ILC2s and inhibiting the development of ILC3 lineage. Simultaneously, G9a is crucial for promoting the expression of ILC2s-related genes in mature ILC2s. Additionally, studies reported that ILCs from Gfi1-deficient mice exhibited reduced ILC2 frequencies and dysregulated expression of ILC3-related genes<sup>[204]</sup>, a phenotype similar to G9a-deficient ILC2s. Furthermore, Gfi1 has been shown to directly interact with G9a<sup>[205]</sup>, suggesting that the G9a-Gfi1 interaction may play a crucial role in the epigenetic regulation of ILC development.

#### **2.3.2 Epigenetic Modifications Modulate Lineage Development and Activation of Natural Killer Cell**

Holmes et al. elucidated the transcriptional and epigenetic networks governing human NK cell differentiation, identifying Bcl11b as a central regulatory factor in several



steps of NK cell differentiation<sup>[206]</sup>. BCL11B maintains a transcriptional program that enhances NK cell receptor expression, effector functions, and proliferation in response to viral infections<sup>[206]</sup>. The level of DNA methylation within Fcgr3a promoter negatively correlates with CD16a levels during NK cell maturation<sup>[207]</sup>. ID2 also plays a critical role in NK cell development. Nandakumar et al. observed severely impaired NK cell development in mice lacking the histone deubiquitinase MYSM1, which led to suppressed Id2 expression. This deficiency occurred because MYSM1 interacts with NFIL3, facilitating their recruitment to the Id2 gene locus. This interaction shifts the chromatin of the Id2 gene region from a repressed to an activated state, crucially promoting NK cell development<sup>[208]</sup>. This suggests that MYSM1 is a pivotal epigenetic regulator of NK cell development, controlling the chromatin status of the Id2 gene region, which is crucial for NK cell development, and transcriptional regulation of Id2. Moreover, miRNAs have emerged as essential regulators in NK cell development. Reduced levels of miR-181 inhibit the differentiation of hematopoietic progenitor cells (HPCs) into mature NK cells, whereas its overexpression increases NK cell differentiation. Additionally, miR-181 expression in NK progenitors increases as they progress through differentiation stages. Mechanistic studies indicate that miR-181 influences NK cell differentiation by downregulating the Notch signaling pathway through its target, the NF- $\kappa$ B essential modulator (nemo)-like kinase<sup>[209]</sup>. Notch signaling appears to be indispensable during NK cell maturation<sup>[210]</sup>.

### **2.3.3 Discussion on Epigenetic Modifications Regulation of the Lineage Development and Activation of Innate Lymphoid Cells**

As mentioned above, epigenetic modifications play an indispensable role in the development and plasticity of ILCs, responding to the local microenvironment shaped during homeostasis and infection, as well as disease signals. Establishing a comprehensive TFs network and epigenetic modification landscape during ILC lineage development would aid in understanding and developing strategies for reprogramming progenitor cells or ILCs using epigenetic modifications and their associated enzymes. This could regulate the host's innate immune homeostasis.

### **3 The Role of Epigenetic Modification in Pathogen Infection**

Epigenetic modifications operate at various levels, including transcription, post-transcriptional modifications, and post-translational modifications, to regulate innate immune signaling upon infection, thereby preventing infection and inflammatory damage. Upon pathogen invasion, IICs utilize PRRs to detect pathogens, rapidly transmitting the infection signals to the cell nucleus. This process shapes a specific epigenetic modification pattern in IICs and alters the expression of relevant epigenetic enzyme genes. In turn, specific epigenetic modification patterns confer IICs with a distinctive gene expression profile. Subsequently, by activating or suppressing PRRs and regulating the transcription of pro-inflammatory cytokines and antimicrobial peptides (AMPs), these patterns help balance and sustain the intensity of the innate immune response.

#### **3.1 Epigenetic Modifications Modulate the PRRs of IICs to Balance the Innate Immune Response**

PRRs are essential components of the IICs that perceive PAMPs and DAMPs. They primarily include Toll-like Receptors (TLRs), RIG-I-like Receptors (RLRs), and Nod-like Receptors (NLRs). Activation of these PRRs induces the production of cytokines and interferons, thereby initiating antimicrobial and antiviral responses in IICs. Gene expression of PRRs and their signaling molecules is subject to epigenetic regulation, encompassing processes ranging from the initiation of transcription mediated by DNA methylation, histone methylation and acetylation to chromatin remodeling. Additionally, RNA stability and translation rates are modulated by RNA-binding proteins (RBPs) and m<sup>6</sup>A modification proteins.

##### **3.1.1 Transcriptional Regulation**

The transcription initiation of PRRs and their signaling molecules represents a crucial checkpoint for IICs to resist pathogenic invasions. Studies have revealed that macrophages, during the early stages of bacterial infection, activate TLR4 by promoting the generation of acetyl-CoA from glucose<sup>[211]</sup>. This enhances histone acetylation, independent of HDACs and HATs. Subsequently, the signaling cascade through MyD88 and TRIF leads to the activation of ATP citrate lyase, further

promoting the transcription of LPS-induced gene sets<sup>[211]</sup> (Figure 4A). This research underscores the potential of targeting the metabolic-histone acetylation modification axis to regulate innate immune responses against invading pathogens. The histone methyltransferase Ezh1, dependent on lysine methyltransferase activity, directly binds to the proximal promoter of Tollip (TLRs interacting protein), a negative regulator of TLR signaling, and maintains H3K27me3 to suppress Tollip transcription. Consequently, Ezh1 promotes the production of inflammatory cytokines triggered by TLRs by inhibiting the negative regulatory factor Tollip, contributing to the full activation of innate immune responses against invading pathogens<sup>[212]</sup>. Furthermore, macrophage Ezh2, by suppressing SIRT1-mediated deacetylation, maintains H3K27ac in the promoter of lncRNA-Neat1<sup>[213]</sup> (Figure 4B). The increased chromatin accessibility facilitates p65-mediated transcription of lncRNA-Neat1, a critical mediator in the assembly and activation of NLRs-mediated inflammasomes. Simultaneously, p53 competes for binding to the lncRNA-Neat1 promoter region, recruiting the deacetylase SIRT1 for H3K27 deacetylation. This antagonizes Ezh2-induced transcription of lncRNA-Neat1 and downstream inflammasome activation. This suggests that Ezh2 and p53, through competitive interactions, maintain H3K27ac, thereby participating in the transcriptional activation of lncRNA-Neat1 and subsequently regulating NLRs activation<sup>[213]</sup>. The H3K4-specific histone methyltransferase WDR5 and H3K79 methyltransferase DOT1L, by mediating histone methylation, enhance the binding of interferon regulatory factor 3 (IRF3) to the Nlrp3 promoter and promote Nlrp3 transcription in liver macrophages induced by STING, thereby enhancing cell pyroptosis and liver inflammation<sup>[214]</sup> (Figure 4B). In primary macrophages, KMT2B directly promotes the transcription of the Pigg gene by increasing H3K4me3 levels at its promoter<sup>[215]</sup>. The product of Pigg is essential for proper membrane anchoring of CD14, an accessory receptor for TLR3-mediated signaling.

During the activation of macrophages by LPS, HDAC3 is recruited to ATF2 binding sites, activating Tlr4 transcription<sup>[134]</sup>. Loss of HDAC3 in macrophages protects mice from lethal exposure to LPS<sup>[134,216]</sup>. Additionally, HDAC3, independent

of its classical nuclear histone deacetylation function, translocates to mitochondria during macrophage NLRP3 inflammasome activation (Figure 4B). HDAC3 deacetylates the HADHA at the K303 site during fatty acid oxidation, reducing its catalytic activity. This, in turn, hampers macrophage fatty acid oxidation metabolism efficiency, ultimately promoting the maturation and secretion of IL-1 $\beta$  mediated by the NLRP3 inflammasome, exacerbating inflammatory responses, and inducing inflammatory damage to the organism<sup>[216]</sup>.




Figure 4: Epigenetic mechanisms mediating PRRs transcription signaling.

A. Bacterial infection activates TLR4, leading to the MyD88/TRIF-dependent pathway that promotes glucose metabolism and the production of CoA. This, in turn, regulates histone acetylation modifications, enhancing the transcription of immune response genes. B. The interplay between the pattern recognition receptor NLRP3 and epigenetic modifications.

### 3.1.2 Post-Transcriptional Regulation

The protein expression of various signaling molecules of PRRs is extensively subject to transcriptional post-regulation, with a critical contribution from RNA-binding proteins (RBPs) and m<sup>6</sup>A modification proteins. Luo et al. discovered that in LPS-induced sepsis, METTL3 facilitates m<sup>6</sup>A modification of Tlr4 mRNA in neutrophils, enhancing Tlr4 mRNA translation rate and inhibiting its degradation. This leads to elevated levels of TLR4 protein, ultimately promoting TLR4 signaling

activation in neutrophils, exacerbating the outbreak of inflammation, and subsequently increasing mortality rates<sup>[217]</sup>. RNA-binding protein DDX5 interacts with METTL3 and METTL14 to form an m<sup>6</sup>A writing complex. This complex adds m<sup>6</sup>A to the transcripts of Tlr2 and Tlr4, promoting their decay through RNA degradation mediated by YTHDF2. As a result, the expression of TLR2/4 is reduced, balancing the inflammatory response induced by bacterial infection<sup>[218]</sup> (Figure 5). In our previous studies, we found that YTHDF1, by recognizing the key factor m<sup>6</sup>A modification in TLRs and NLRs signaling, participates in innate immune responses<sup>[219]</sup>. Traf6, a crucial regulatory factor in TLRs and subsequent NF-κB signaling, is recognized by RNA-binding protein DDX60 through its HELICc domain, interacting with Traf6 mRNA. DDX60 also utilizes its HELICc domain to interact with the P/Q/N domain of YTHDF1, recruiting YTHDF1. Subsequently, YTHDF1 recognizes the m<sup>6</sup>A of Traf6 mRNA through YTH domain, promoting Traf6 translation and its mediation of intestinal immune responses<sup>[219]</sup> (Figure 5). Additionally, both our lab and other researchers have discovered that YTHDF1 directly recognizes the m<sup>6</sup>A modification in macrophage Nlrp3 mRNA<sup>[220,221]</sup> (Figure 5). This promotes its translation rate in polysomes, leading to NLRP3 inflammasome activation and, consequently, facilitating intestinal bacterial infection. Mice lacking YTHDF1 are protected from various detrimental effects of bacterial infections<sup>[220,221]</sup>. Similarly, after viral infection, RNA-binding protein DDX46 recruits ALKBH5, which, through the DEAD helicase domain of DDX46, removes the m<sup>6</sup>A modification from transcripts associated with antiviral responses such as Mavs, Traf3, and Traf6<sup>[222]</sup>. This inhibits their nuclear export, preventing their translation in the ribosome and suppressing interferon production, ultimately suppressing the antiviral innate immune response<sup>[222]</sup>. In addition, miRNAs also participate in the regulation of post-transcriptional modifications of TLRs. For instance, in alveolar macrophages from patients with severe asthma, there is a significant reduction in the expression of TLR7, accompanied by a substantial increase in the expression of miR-150, miR-152, and miR-375. Further investigations have revealed that these three miRNAs collectively inhibit the expression of TLR7, leading to a reduction in IFN production

and facilitating viral invasion<sup>[223,224]</sup>.




Figure 5. Epigenetic mechanisms mediating post-transcriptional regulation of PRRs  
Bacterial infection activates the NF-κB-p65 signaling pathway through TLR4, leading to the transcription of Tlr4, Tlr2, Traf6, and nlr3 genes. Subsequently, these Tlr4, Tlr2, Traf6, and nlr3 RNAs are recognized by DDX60, which recruits METTL3 to promote their m<sup>6</sup>A modification. Under the influence of YTHDF1, this modification enhances their translation in ribosomes. This process subsequently triggers a positive feedback loop that regulates the expression of TLR4 and NLRP3.

### 3.2 Epigenetic Modifications Modulate the Innate Immune Effector of IICs to Balance the Innate Immune Response

#### 3.2.1 Pro-Inflammatory Cytokines

Epigenetic modifications play a crucial role in modulating the chromatin remodeling of IICs in response to innate immune responses. For instance, RelB induces facultative heterochromatin formation by directly interacting with G9a. Subsequently, heterochromatin protein and G9a form a complex at the Il-1β promoter, promoting Il-1β transcription<sup>[225]</sup>. Prolonged stimulation of macrophages with LPS increases the expression of miR-221 and miR-222, which, in turn, suppresses Brg1, an



ATPase subunit of the SWI/SNF. This alteration leads to changes in the level or composition of the SWI/SNF complex, thereby inhibiting the transcription of STAT2-dependent pro-inflammatory cytokine genes<sup>[58]</sup>. Similarly, antisense IL-7 is a recently discovered lncRNA in humans and mice. Mechanistic studies reveal that lncRNA-IL-7-AS interacts with p300, regulating the level of histone acetylation in the IL-6 gene promoter region. Simultaneously, the complex formed by lncRNA-IL-7-AS and p300 participates in the regulation of SWI/SNF-mediated chromatin remodeling at the IL-6 gene promoter, promoting IL-6 transcription<sup>[57]</sup> (Figure 6A).

Furthermore, histone methylation and acetylation are major factors in the transcription of pro-inflammatory cytokines in IICs. For example, Ash11, through the SET domain's H3K4 methyltransferase activity, induces H3K4 methylation at the *Tnfaip3* promoter, enhancing the expression of the deubiquitinase A20. Ash11 promotes TRAF6 deubiquitination mediated by A20, inhibiting the NF- $\kappa$ B pathway and subsequent production of IL-6 and Tnf- $\alpha$ , protecting mice from sepsis (Figure 6B). The histone methyltransferase SETD4 rapidly translocates from the cytoplasm to the nucleus upon LPS stimulation, positively regulating IL-6 and Tnf- $\alpha$  transcription in macrophages by directly activating H3K4 methylation at the gene promoters, independent of upstream regulatory factors such as p38, ERK, JNK, p65, and I $\kappa$ B $\alpha$ <sup>[226]</sup>. Additionally, histone deacetylation modification is a mechanism that inhibits the transcription of pro-inflammatory cytokines during the resolution of inflammation. For example, Tet2, independent of DNA methylation, inhibits IL-6 transcription by recruiting HDAC2. Compared to wild-type mice, Tet2-deficient mice are more susceptible to endotoxic shock and dextran sulfate sodium-induced colitis, leading to aggravated inflammation and IL-6 storm<sup>[227]</sup> (Figure 6C). In addition, during the polarization process of porcine macrophages stimulated by LPS, the expression of DNTM3b is reduced, leading to a downregulation of the methylation level of the Tnf- $\alpha$  gene promoter, thereby promoting its transcription<sup>[228]</sup>. Similarly, porcine reproductive and respiratory syndrome virus (PRRSV) infection in porcine macrophages inhibits the expression of FTO, resulting in an increase in m<sup>6</sup>A methylation levels. This, in turn, enhances the expression of IL-13 through the



functional modulation of m<sup>6</sup>A modifications<sup>[229]</sup>.

In summary, these studies directly indicate that epigenetic modifications regulate the transcription of cytokines in IICs in response to pathogenic infections through chromatin remodeling, histone modifications, DNA and RNA methylation, and ncRNAs. However, it remains unclear whether the sustained development of IICs will reciprocally regulate epigenetic modifications, thus reversing the activation state of IICs and forming a feedback loop to activate and inhibit ILCs-mediated innate immune responses timely.




Figure 6. Epigenetic mechanisms mediating the transcription of innate immune factors.

A. Lnc-IL7-AS and H3K27ac in the regulation of Il6 transcription. B. ASH11-mediated H3K4me regulation of Il6 and Tnf- $\alpha$  transcription. C. TET2 and HDAC2 in regulation of Il6 transcription via H3K27ac. D. Histone acetylation levels on AMPs gene loci correlate positively with AMP transcription. E. DNA methylation levels at AMPs promoters correlate negatively with AMP transcription.

### 3.2.2 Antimicrobial Peptides

AMPs are a class of cationic host defense peptides that not only possess direct bactericidal properties but also enhance the functions of various IICs through immunomodulation, thereby resisting pathogenic infections<sup>[116]</sup>. Currently, research on the epigenetic regulation mechanisms of AMPs in IICs predominantly focuses on histone acetylation. For instance, HDACi has been confirmed as effective inducers of

AMPs<sup>[230,231]</sup> (Figure 6D). A groundbreaking study by Garcia et al. established a connection between histone acetylation, AMPs transcription, and intracellular bacterial infection. Infections by *Bacillus thuringiensis* in THP-1 macrophages resulted in the silencing of AMPs expression<sup>[232]</sup>. Mechanistic investigations revealed that infection promoted the HDAC1 expression. Increased binding of HDAC1 to the AMPs gene promoter was observed, leading to a significant reduction in histone H3 acetylation in infected cells. This ultimately inhibited the open chromatin state and gene expression of AMPs. Overexpression of HDAC1 enhanced bacterial infectivity, while HDAC1 inhibition significantly reduced bacterial load<sup>[232]</sup>. Further studies demonstrated that during bacterial infection, inhibition of histone deacetylase promoted acetylation of the p65 K310 lysine residue by histone acetyltransferase p300, enhancing the expression of the hBD2 gene without a concomitant increase in inflammatory cytokines, thereby reinforcing antimicrobial immune modulation capabilities<sup>[233]</sup>.

Regarding the regulation of AMPs transcription by DNA methylation, research indicates that DNA methylation in the AMPs promoter region leads to transcriptional downregulation, increasing the host's susceptibility to bacterial infections<sup>[234-236]</sup> (Figure 6D). In our previous investigation into the relationship between RNA m<sup>6</sup>A methylation and AMPs expression, we discovered an interaction between the TF FOXO6 and METTL3. This interaction triggered the transcription of GPR161 and its subsequent regulation of AMPs transcription, contributing to the resistance against *Enterotoxigenic Escherichia coli*-induced inflammatory responses<sup>[237]</sup>. However, the precise mechanisms of DNA methylation and RNA methylation in regulating AMPs transcription or post-transcriptional modifications remain to be studied.

#### **4 Conclusion and Prospects**

A functional immune system relies on the precise and swift regulation of IICs in response to ever-changing signals within their ecological niches. This capability hinges upon the diverse functionality and high adaptability of these cells. Disruption of the plasticity of IICs can trigger innate immune dysregulation and excessive inflammatory responses, ultimately leading to the onset of immune-related diseases in

the host. Epigenetic modifications play a pivotal role in maintaining the functionality and plasticity of IICs, as well as in the innate immune responses associated with infections and chronic inflammation. Current research primarily focuses on elucidating how epigenetics undergo reprogramming and how this reprogrammed epigenome, in turn, establishes functionally specific gene expression patterns in innate immunity. The establishment of comprehensive single-cell epigenomic and transcriptomic profiles of IICs, particularly during *in vivo* innate immune responses, at the single-cell and single-molecule levels through single-cell transcriptomics and single-cell epigenomic sequencing technologies, is poised to decode the epigenetic blueprint of innate immunity comprehensively. Targeting the regulation of epigenetic modifications in IICs is considered a promising strategy. Utilizing epigenetic inhibitors to remove disease-associated epigenetic modifications that contribute to altered gene expression patterns in the host, may aid in re-establishing immune homeostasis, pathogen clearance, and mitigating tissue inflammation. However, epigenetic inhibitors typically exert systemic effects when used in the human body, making it challenging to specifically target key subsets of IICs. Moreover, some epigenetic inhibitors used in clinical trials demonstrate broad effects lacking specificity for gene loci, potentially reactivating non-beneficial or silenced genomic sequences. Epigenetic drugs often exhibit inherent biological activity, thus necessitating researchers to rely on medicinal chemistry design to enhance compound selectivity and specificity, ensuring their safety by avoiding toxicity. This aspect holds particular importance, particularly in the context of recurrent infections or ailments marked by sustained inflammation, demanding prolonged therapeutic strategies. Additionally, the combination of different epigenetic inhibitors might augment the efficacy of each drug. For instance, the combined use of DNMTi and HDACi increased M2 polarization in lung tissues, ameliorating acute lung injury caused by sepsis. This suggests that combination therapy might be the most beneficial approach for treating particular pathological conditions; however, further investigation is imperative to substantiate this premise.

## 5 Important Issues to Be Addressed in The Future

- 1) It utilizes recently developed cell lineage tracing tools<sup>[238]</sup>, investigating longitudinally and in multiple dimensions at the single-cell level, accurately characterizing the phenotypic plasticity and epigenome of IICs at each critical time point during lineage development and differentiation. This aims to identify the key TFs and epigenetic modifications defining the state of IICs and determine whether the plasticity of these cells could be extended through controlling epigenetic modifications to treat associated diseases.
- 2) The conservation of lncRNAs is relatively low, and their folding and structure heterogeneity presents significant challenges in related studies. Therefore, our current understanding of lncRNAs in regulating the fate and function of IICs still needs to be improved. Developing third-generation long-read RNA sequencing, ultra-high-resolution imaging techniques, and gene editing technologies offers new opportunities for studying lncRNAs. Leveraging machine learning to analyze vast datasets encompassing genomics, epigenomics, transcriptomics, proteomics, and phenomics of IICs can aid in identifying causal relationships and pathways. This approach may help discover crucial lncRNAs regulating IICs fate. With the continued advancement in the research of the biological functions and mechanisms of lncRNAs, targeted lncRNA therapies are poised to play a significant role in disease diagnosis, targeted treatment, and drug development.
- 3) How will integrative analysis of epigenomics and other omics data transform our understanding of the lineage development, differentiation, and activation of IICs? While comprehensive epigenomic and transcriptomic studies have been conducted at the macrophage subtype level, a method to demonstrate the total epigenetic modification rate in individual macrophages is yet to be established. If such an approach is developed, could it accurately predict macrophage development or polarization states? Moreover, can it explain the functional and phenotypic differences between early-activated macrophage polarization for pathogen resistance and long-term activation leading to host damage? If this concept can be realized, doctors would only need to collect a few milliliters of a

patient's blood, isolate macrophages using biochemical instrumentation, and detect their overall epigenetic modification rate through appropriate methods. This would enable doctors to determine the state of immune activation in patients, greatly assisting in the targeted treatment of patients and reducing the misdiagnosis of clinical symptoms.

- 4) Achieving specific epigenetic modifications targeting particular subsets of IICs is a critical concern. Additionally, the combined use of different epigenetic inhibitors has shown improved efficacy. Can similar epigenetic drugs induce synergistic effects by acting on various subsets of IICs? However, these issues are of clinical significance and require not only researchers to conduct specific targeted experiments and safety studies in model organisms such as mice to provide a theoretical basis, but also for doctors to utilize these reliable results to conduct clinical trials on a large scale by recruiting patients for individual testing and analysis. This approach is necessary to address the questions above.
- 5) Can highly specific epigenetic inhibitors retain biological activity while reducing toxicity?
- 6) Can combining immunotherapy with epigenetic therapy lead to more effective treatment strategies?
- 7) Exploring additional epigenetic mechanisms such as chromatin condensation, DNA (hydroxy)methylation, and gaining deeper insights into the roles of enhancers and 3D chromatin architecture. These novel epigenetic mechanisms may pave a new path towards the treatment of specific, previously untreatable diseases.

### **Author Contributions**

JF conceived and wrote the review, YW provided the writing guidance.

### **Funding**

The project was supported by the Zhejiang Provincial Key R&D Program of China (2021C02008), the China Agriculture Research System of MOF and MARA (CARS-35).

## References

- [1]. Zhang, Q. & Cao, X. Epigenetic Remodeling in Innate Immunity and Inflammation [J] ANNUAL REVIEW OF IMMUNOLOGY. 2021, **39**, 279-311.
- [2]. Guo, Z., Wang, L., Liu, H. et al. Innate Immune Memory in Monocytes and Macrophages: The Potential Therapeutic Strategies for Atherosclerosis [J] CELLS. 2022, **11**
- [3]. Li, D. & Wu, M. Pattern recognition receptors in health and diseases [J] SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2021, **6**, 291.
- [4]. Locati, M., Curtale, G. & Mantovani, A. Diversity, Mechanisms, and Significance of Macrophage Plasticity [J] ANNUAL REVIEW OF PATHOLOGY. 2020, **15**, 123-147.
- [5]. Tsioumpkou, M., Krijgsman, D., Leusen, J. H. W. et al. The Role of Cytokines in Neutrophil Development, Tissue Homing, Function and Plasticity in Health and Disease [J] CELLS. 2023, **12**
- [6]. Cao, X. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease [J] NATURE REVIEWS IMMUNOLOGY. 2016, **16**, 35-50.
- [7]. Amatullah, H. & Jeffrey, K. L. Epigenome-metabolome-microbiome axis in health and IBD [J] CURRENT OPINION IN MICROBIOLOGY. 2020, **56**, 97-108.
- [8]. Martins, R., Carlos, A. R., Braza, F. et al. Disease Tolerance as an Inherent Component of Immunity [J] ANNUAL REVIEW OF IMMUNOLOGY. 2019, **37**, 405-437.
- [9]. Liotti, A., Ferrara, A. L., Loffredo, S. et al. Epigenetics: An opportunity to shape innate and adaptive immune responses [J] IMMUNOLOGY. 2022, **167**, 451-470.
- [10]. Fraschilla, I., Amatullah, H. & Jeffrey, K. L. One genome, many cell states: epigenetic control of innate immunity [J] CURRENT OPINION IN IMMUNOLOGY. 2022, **75**, 102173.
- [11]. Hoeksema, M. A. & de Winther, M. P. Epigenetic Regulation of Monocyte and Macrophage Function [J] ANTIOXIDANTS AND REDOX SIGNALING. 2016, **25**, 758-774.
- [12]. Saeed, S., Quintin, J., Kerstens, H. H. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity [J] SCIENCE. 2014, **345**, 1251086.
- [13]. de la Rica, L., Rodríguez-Ubreva, J., García, M. et al. PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation [J] GENOME BIOLOGY. 2013, **14**, R99.
- [14]. Bonder, M. J., Luijk, R., Zhernakova, D. V. et al. Disease variants alter transcription factor levels and methylation of their binding sites [J] NATURE GENETICS. 2017, **49**, 131-138.
- [15]. Dekkers, K. F., Neele, A. E., Jukema, J. W. et al. Human monocyte-to-macrophage differentiation involves highly localized gain and loss of DNA methylation at transcription factor binding sites [J] EPIGENETICS CHROMATIN. 2019, **12**, 34.
- [16]. Li, X., Ye, Y., Peng, K. et al. Histones: The critical players in innate immunity [J] FRONTIERS IN IMMUNOLOGY. 2022, **13**, 1030610.
- [17]. Álvarez-Errico, D., Vento-Tormo, R., Sieweke, M. et al. Epigenetic control of myeloid cell differentiation, identity and function [J] NATURE REVIEWS IMMUNOLOGY. 2015, **15**, 7-17.
- [18]. Chen, S., Yang, J., Wei, Y. et al. Epigenetic regulation of macrophages: from homeostasis maintenance to host defense [J] CELLULAR & MOLECULAR IMMUNOLOGY. 2020, **17**, 36-49.

- [19]. Han, P. & Chang, C. P. Long non-coding RNA and chromatin remodeling [J] *RNA BIOLOGY*. 2015, **12**, 1094-1098.
- [20]. Li, X., Wu, Z., Fu, X. et al. lncRNAs: insights into their function and mechanics in underlying disorders [J] *MUTATION RESEARCH - REVIEWS IN MUTATION RESEARCH*. 2014, **762**, 1-21.
- [21]. Sendinc, E. & Shi, Y. RNA m6A methylation across the transcriptome [J] *MOLECULAR CELL*. 2023, **83**, 428-441.
- [22]. Tang, J., Wang, X., Xiao, D. et al. The chromatin-associated RNAs in gene regulation and cancer [J] *MOLECULAR CANCER*. 2023, **22**, 27.
- [23]. Boulias, K. & Greer, E. L. Biological roles of adenine methylation in RNA [J] *NATURE REVIEWS GENETICS*. 2023, **24**, 143-160.
- [24]. Yang, J., Xu, J., Wang, W. et al. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets [J] *SIGNAL TRANSDUCTION AND TARGETED THERAPY*. 2023, **8**, 210.
- [25]. Wu, H. & Zhang, Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation [J] *GENES & DEVELOPMENT*. 2011, **25**, 2436-2452.
- [26]. Ginno, P. A., Gaidatzis, D., Feldmann, A. et al. A genome-scale map of DNA methylation turnover identifies site-specific dependencies of DNMT and TET activity [J] *NATURE COMMUNICATIONS*. 2020, **11**, 2680.
- [27]. Lyko, F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation [J] *NATURE REVIEWS GENETICS*. 2018, **19**, 81-92.
- [28]. Schmidl, C., Delacher, M., Huehn, J. et al. Epigenetic mechanisms regulating T-cell responses [J] *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*. 2018, **142**, 728-743.
- [29]. Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control [J] *NATURE REVIEWS GENETICS*. 2016, **17**, 487-500.
- [30]. Schübeler, D. Function and information content of DNA methylation [J] *NATURE*. 2015, **517**, 321-326.
- [31]. Yin, Y., Morgunova, E., Jolma, A. et al. Impact of cytosine methylation on DNA binding specificities of human transcription factors [J] *SCIENCE*. 2017, **356**
- [32]. Jones, P. L., Veenstra, G. J., Wade, P. A. et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription [J] *NATURE GENETICS*. 1998, **19**, 187-191.
- [33]. Arechederra, M., Daian, F., Yim, A. et al. Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer [J] *NATURE COMMUNICATIONS*. 2018, **9**, 3164.
- [34]. Han, H., Cortez, C. C., Yang, X. et al. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter [J] *HUMAN MOLECULAR GENETICS*. 2011, **20**, 4299-4310.
- [35]. Mittelstaedt, N. N., Becker, A. L., de Freitas, D. N. et al. DNA Methylation and Immune Memory Response [J] *CELLS*. 2021, **10**
- [36]. Xiao, C. L., Zhu, S., He, M. et al. N(6)-Methyladenine DNA Modification in the Human Genome [J] *MOLECULAR CELL*. 2018, **71**, 306-318.e307.
- [37]. Kong, Y., Cao, L., Deikus, G. et al. Critical assessment of DNA adenine methylation in eukaryotes using quantitative deconvolution [J] *SCIENCE*. 2022, **375**, 515-522.
- [38]. Boulias, K. & Greer, E. L. Means, mechanisms and consequences of adenine methylation in



- DNA [J] NATURE REVIEWS GENETICS. 2022, **23**, 411-428.
- [39]. Feng, X. & He, C. Mammalian DNA N(6)-methyladenosine: Challenges and new insights [J] MOLECULAR CELL. 2023, **83**, 343-351.
- [40]. Qin, W., Scicluna, B. P. & van der Poll, T. The Role of Host Cell DNA Methylation in the Immune Response to Bacterial Infection [J] FRONTIERS IN IMMUNOLOGY. 2021, **12**, 696280.
- [41]. Pacis, A., Tailleux, L., Morin, A. M. et al. Bacterial infection remodels the DNA methylation landscape of human dendritic cells [J] GENOME RESEARCH. 2015, **25**, 1801-1811.
- [42]. Pacis, A., Mailhot-Léonard, F., Tailleux, L. et al. Gene activation precedes DNA demethylation in response to infection in human dendritic cells [J] PROC NATL ACAD SCI U S A. 2019, **116**, 6938-6943.
- [43]. Lutz, P. E., Chay, M. A., Pacis, A. et al. Non-CG methylation and multiple histone profiles associate child abuse with immune and small GTPase dysregulation [J] NATURE COMMUNICATIONS. 2021, **12**, 1132.
- [44]. Lau, C. M., Adams, N. M., Geary, C. D. et al. Epigenetic control of innate and adaptive immune memory [J] NATURE IMMUNOLOGY. 2018, **19**, 963-972.
- [45]. Jain, N., Shahal, T., Gabrieli, T. et al. Global modulation in DNA epigenetics during pro-inflammatory macrophage activation [J] EPIGENETICS. 2019, **14**, 1183-1193.
- [46]. McErlean, P., Bell, C. G., Hewitt, R. J. et al. DNA Methylome Alterations Are Associated with Airway Macrophage Differentiation and Phenotype during Lung Fibrosis [J] AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2021, **204**, 954-966.
- [47]. Zhang, X., He, D., Xiang, Y. et al. DYSF promotes monocyte activation in atherosclerotic cardiovascular disease as a DNA methylation-driven gene [J] TRANSLATIONAL RESEARCH. 2022, **247**, 19-38.
- [48]. Skvortsova, K., Iovino, N. & Bogdanović, O. Functions and mechanisms of epigenetic inheritance in animals [J] NATURE REVIEWS MOLECULAR CELL BIOLOG. 2018, **19**, 774-790.
- [49]. Pradeepa, M. M., Grimes, G. R., Kumar, Y. et al. Histone H3 globular domain acetylation identifies a new class of enhancers [J] NATURE GENETICS. 2016, **48**, 681-686.
- [50]. Comer, B. S., Ba, M., Singer, C. A. et al. Epigenetic targets for novel therapies of lung diseases [J] PHARMACOLOGY & THERAPEUTICS. 2015, **147**, 91-110.
- [51]. Bernstein, B. E., Kamal, M., Lindblad-Toh, K. et al. Genomic maps and comparative analysis of histone modifications in human and mouse [J] CELL. 2005, **120**, 169-181.
- [52]. Daskalaki, M. G., Tsatsanis, C. & Kampranis, S. C. Histone methylation and acetylation in macrophages as a mechanism for regulation of inflammatory responses [J] JOURNAL OF CELLULAR PHYSIOLOG. 2018, **233**, 6495-6507.
- [53]. Zhao, Z., Su, Z., Liang, P. et al. USP38 Couples Histone Ubiquitination and Methylation via KDM5B to Resolve Inflammation [J] ADVANCED SCIENCE. 2020, **7**, 2002680.
- [54]. Yang, L., Jia, R., Ge, T. et al. Extrachromosomal circular DNA: biogenesis, structure, functions and diseases [J] SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2022, **7**, 342.
- [55]. Kuzelova, A., Dupacova, N., Antosova, B. et al. Chromatin Remodeling Enzyme Snf2h Is Essential for Retinal Cell Proliferation and Photoreceptor Maintenance [J] CELLS. 2023, **12**
- [56]. Narlikar, G. J., Sundaramoorthy, R. & Owen-Hughes, T. Mechanisms and functions of

- ATP-dependent chromatin-remodeling enzymes [J] *CELL*. 2013, **154**, 490-503.
- [57]. Liu, X., Lu, Y., Zhu, J. et al. A Long Noncoding RNA, Antisense IL-7, Promotes Inflammatory Gene Transcription through Facilitating Histone Acetylation and Switch/Sucrose Nonfermentable Chromatin Remodeling [J] *JOURNAL OF IMMUNOLOGY*. 2019, **203**, 1548-1559.
- [58]. Seeley, J. J., Baker, R. G., Mohamed, G. et al. Induction of innate immune memory via microRNA targeting of chromatin remodelling factors [J] *NATURE*. 2018, **559**, 114-119.
- [59]. Desrosiers, R., Friderici, K. & Rottman, F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells [J] *PROC NATL ACAD SCI U S A*. 1974, **71**, 3971-3975.
- [60]. Bokar, J. A., Shambaugh, M. E., Polayes, D. et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase [J] *RNA*. 1997, **3**, 1233-1247.
- [61]. Jia, G. F., Fu, Y., Zhao, X. et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO [J] *Nat Chem Biol*. 2011, **7**, 885-887.
- [62]. Zheng, G. Q., Dahl, J. A., Niu, Y. M. et al. ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility [J] *Mol Cell*. 2013, **49**, 18-29.
- [63]. Yao, Q. J., Sang, L. N., Lin, M. H. et al. Mettl3-Mettl14 methyltransferase complex regulates the quiescence of adult hematopoietic stem cells [J] *Cell Res*. 2018, **28**, 952-954.
- [64]. Kobayashi, M., Ohsugi, M., Sasako, T. et al. The RNA Methyltransferase Complex of WTAP, METTL3, and METTL14 Regulates Mitotic Clonal Expansion in Adipogenesis [J] *Mol Cell Biol*. 2018, **38**
- [65]. Schwartz, S., Mumbach, M. R., Jovanovic, M. et al. Perturbation of m6A Writers Reveals Two Distinct Classes of mRNA Methylation at Internal and 5' Sites [J] *Cell Rep*. 2014, **8**, 284-296.
- [66]. Scholler, E., Weichmann, F., Treiber, T. et al. Interactions, localization, and phosphorylation of the m(6)A generating METTL3-METTL14-WTAP complex [J] *Rna*. 2018, **24**, 499-512.
- [67]. Riquelme-Barrios, S., Pereira-Montecinos, C., Valiente-Echeverria, F. et al. Emerging Roles of N-6-Methyladenosine on HIV-1 RNA Metabolism and Viral Replication [J] *Front Microbiol*. 2018, **8**
- [68]. Meyer, K. D., Saletore, Y., Zumbo, P. et al. Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3' UTRs and near Stop Codons [J] *Cell*. 2012, **149**, 1635-1646.
- [69]. Patil, D. P., Chen, C. K., Pickering, B. F. et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression [J] *Nature*. 2016, **537**, 369-+.
- [70]. Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S. et al. Topology of the human and mouse m(6)A RNA methylomes revealed by m(6)A-seq [J] *Nature*. 2012, **485**, 201-U284.
- [71]. Wang, X., Lu, Z. K., Gomez, A. et al. N-6-methyladenosine-dependent regulation of messenger RNA stability [J] *Nature*. 2014, **505**, 117-+.
- [72]. Wang, X., Zhao, B. S., Roundtree, I. A. et al. N-6-methyladenosine Modulates Messenger RNA Translation Efficiency [J] *Cell*. 2015, **161**, 1388-1399.
- [73]. Shi, H., Wang, X., Lu, Z. et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA [J] *Cell Res*. 2017, **27**, 315-328.
- [74]. Xu, C., Wang, X., Liu, K. et al. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain [J] *Nat Chem Biol*. 2014, **10**, 927-929.
- [75]. Hsu, P. J., Zhu, Y., Ma, H. et al. Ythdc2 is an N(6)-methyladenosine binding protein that

- regulates mammalian spermatogenesis [J] *Cell Res.* 2017, **27**, 1115-1127.
- [76]. Meyer, K. D., Patil, D. P., Zhou, J. et al. 5' UTR m(6)A Promotes Cap-Independent Translation [J] *Cell.* 2015, **163**, 999-1010.
- [77]. Alarcon, C. R., Goodarzi, H., Lee, H. et al. HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events [J] *Cell.* 2015, **162**, 1299-1308.
- [78]. Zhou, W., Wang, X., Chang, J. et al. The molecular structure and biological functions of RNA methylation, with special emphasis on the roles of RNA methylation in autoimmune diseases [J] *CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES.* 2022, **59**, 203-218.
- [79]. Xu, W., Li, J., He, C. et al. METTL3 regulates heterochromatin in mouse embryonic stem cells [J] *Nature.* 2021, **591**, 317-321.
- [80]. Cen, S., Li, J., Cai, Z. et al. TRAF4 acts as a fate checkpoint to regulate the adipogenic differentiation of MSCs by activating PKM2 [J] *EBioMedicine.* 2020, **54**, 102722.
- [81]. Li, Y., Xia, L., Tan, K. et al. N(6)-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2 [J] *Nat Genet.* 2020, **52**, 870-877.
- [82]. Xu, W., He, C., Kaye, E. G. et al. Dynamic control of chromatin-associated m(6)A methylation regulates nascent RNA synthesis [J] *Mol Cell.* 2022, **82**, 1156-1168.e1157.
- [83]. Akhtar, J., Renaud, Y., Albrecht, S. et al. m(6)A RNA methylation regulates promoter-proximal pausing of RNA polymerase II [J] *Mol Cell.* 2021, **81**, 3356-3367.e3356.
- [84]. Liu, J., Dou, X., Chen, C. et al. N(6)-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription [J] *Science.* 2020, **367**, 580-586.
- [85]. Gao, Y., Vasic, R., Song, Y. et al. m(6)A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development [J] *IMMUNITY.* 2020, **52**, 1007-1021.e1008.
- [86]. Yu, J. T., Hu, X. W., Chen, H. Y. et al. DNA methylation of FTO promotes renal inflammation by enhancing m(6)A of PPAR- $\alpha$  in alcohol-induced kidney injury [J] *PHARMACOLOGICAL RESEARCH.* 2021, **163**, 105286.
- [87]. Tong, J., Wang, X., Liu, Y. et al. Pooled CRISPR screening identifies m(6)A as a positive regulator of macrophage activation [J] *SCIENCE ADVANCES.* 2021, **7**
- [88]. Dong, L., Chen, C., Zhang, Y. et al. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8<sup>+</sup> T cell dysfunction and tumor growth [J] *CANCER CELL.* 2021, **39**, 945-957.e910.
- [89]. Carninci, P., Kasukawa, T., Katayama, S. et al. The transcriptional landscape of the mammalian genome [J] *SCIENCE.* 2005, **309**, 1559-1563.
- [90]. Djebali, S., Davis, C. A., Merkel, A. et al. Landscape of transcription in human cells [J] *NATURE.* 2012, **489**, 101-108.
- [91]. Bartel, D. P. MicroRNAs: target recognition and regulatory functions [J] *CELL.* 2009, **136**, 215-233.
- [92]. Brown, C. J., Ballabio, A., Rupert, J. L. et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome [J] *NATURE.* 1991, **349**, 38-44.
- [93]. Ferrè, F., Colantoni, A. & Helmer-Citterich, M. Revealing protein-lncRNA interaction [J] *BRIEFINGS IN BIOINFORMATICS.* 2016, **17**, 106-116.
- [94]. Chen, B., Dragomir, M. P., Yang, C. et al. Targeting non-coding RNAs to overcome cancer therapy resistance [J] *SIGNAL TRANSDUCTION AND TARGETED THERAPY.* 2022, **7**,

- [95]. Statello, L., Guo, C. J., Chen, L. L. et al. Gene regulation by long non-coding RNAs and its biological functions [J] *NATURE REVIEWS MOLECULAR CELL BIOLOGY*. 2021, **22**, 96-118.
- [96]. Chen, Y. G., Satpathy, A. T. & Chang, H. Y. Gene regulation in the immune system by long noncoding RNAs [J] *NATURE IMMUNOLOGY*. 2017, **18**, 962-972.
- [97]. Zhang, Y. & Cao, X. Long noncoding RNAs in innate immunity [J] *CELLULAR & MOLECULAR IMMUNOLOGY*. 2016, **13**, 138-147.
- [98]. Ranzani, V., Rossetti, G., Panzeri, I. et al. The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4 [J] *NATURE IMMUNOLOGY*. 2015, **16**, 318-325.
- [99]. Gomez, J. A., Wapinski, Orly L., Yang, Yul W. et al. The NeST Long ncRNA Controls Microbial Susceptibility and Epigenetic Activation of the Interferon- $\gamma$  Locus [J] *CELL*. 2013, **152**, 743-754.
- [100]. Castellanos-Rubio, A., Fernandez-Jimenez, N., Kratchmarov, R. et al. A long noncoding RNA associated with susceptibility to celiac disease [J] *SCIENCE*. 2016, **352**, 91-95.
- [101]. Wang, P., Xue, Y., Han, Y. et al. The STAT3-binding long noncoding RNA linc-DC controls human dendritic cell differentiation [J] *SCIENCE*. 2014, **344**, 310-313.
- [102]. Atianand, M. K., Hu, W., Satpathy, A. T. et al. A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain Inflammation [J] *CELL*. 2016, **165**, 1672-1685.
- [103]. Carpenter, S., Aiello, D., Atianand, M. K. et al. A Long Noncoding RNA Mediates Both Activation and Repression of Immune Response Genes [J] *SCIENCE*. 2013, **341**, 789-792.
- [104]. Krawczyk, M. & Emerson, B. M. P50-associated COX-2 Extragenic RNA (pacer) activates human COX-2 gene expression by occluding repressive NF- $\kappa$ B p50 complexes [J] *ELIFE*. 2014, **2014**
- [105]. Li, Z., Chao, T. C., Chang, K. Y. et al. The long noncoding RNA THRIL regulates TNF $\alpha$  expression through its interaction with hnRNPL [J] *PROC NATL ACAD SCI U S A*. 2014, **111**, 1002-1007.
- [106]. Wang, P., Xu, J., Wang, Y. et al. An interferon-independent lincRNA promotes viral replication by modulating cellular metabolism [J] *SCIENCE*. 2017, **358**, 1051-1055.
- [107]. Du, M., Yuan, L., Tan, X. et al. The LPS-inducible lincRNA Mirt2 is a negative regulator of inflammation [J] *NATURE COMMUNICATIONS*. 2017, **8**, 2049.
- [108]. Chen, X., He, Y., Zhu, Y. et al. linc-AAM Facilitates Gene Expression Contributing to Macrophage Activation and Adaptive Immune Responses [J] *CELL REPORTS*. 2021, **34**, 108584.
- [109]. Rodríguez-Ubreva, J., Ciudad, L., Gómez-Cabrero, D. et al. Pre-B cell to macrophage transdifferentiation without significant promoter DNA methylation changes [J] *NUCLEIC ACIDS RESEARCH*. 2012, **40**, 1954-1968.
- [110]. Sakai, M., Troutman, T. D., Seidman, J. S. et al. Liver-Derived Signals Sequentially Reprogram Myeloid Enhancers to Initiate and Maintain Kupffer Cell Identity [J] *IMMUNITY*. 2019, **51**, 655-670.e658.
- [111]. Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis [J] *NATURE REVIEWS IMMUNOLOGY*. 2014, **14**, 392-404.
- [112]. Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas [J]

JOURNAL OF CLINICAL INVESTIGATION. 2012, **122**, 787-795.

- [113]. Steinman, R. M. & Idoyaga, J. Features of the dendritic cell lineage [J] IMMUNOLOGICAL REVIEWS. 2010, **234**, 5-17.
- [114]. Gordon, S. & Taylor, P. R. Monocyte and macrophage heterogeneity [J] NATURE REVIEWS IMMUNOLOGY. 2005, **5**, 953-964.
- [115]. Patel, U., Rajasingh, S., Samanta, S. et al. Macrophage polarization in response to epigenetic modifiers during infection and inflammation [J] DRUG DISCOVERY TODAY. 2017, **22**, 186-193.
- [116]. Fu, J., Zong, X., Jin, M. et al. Mechanisms and regulation of defensins in host defense [J] SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023, **8**, 300.
- [117]. Xu, J.-J., Zhu, L., Li, H.-D. et al. DNMT3a-mediated methylation of PSTPIP2 enhances inflammation in alcohol-induced liver injury via regulating STAT1 and NF- $\kappa$ B pathway [J] PHARMACOLOGICAL RESEARCH. 2022, **177**, 106125.
- [118]. Yang, X., Wang, X., Liu, D. et al. Epigenetic regulation of macrophage polarization by DNA methyltransferase 3b [J] MOLECULAR ENDOCRINOLOGY. 2014, **28**, 565-574.
- [119]. Qi, S., Li, Y., Dai, Z. et al. Uhrf1-Mediated Tnf- $\alpha$  Gene Methylation Controls Proinflammatory Macrophages in Experimental Colitis Resembling Inflammatory Bowel Disease [J] JOURNAL OF IMMUNOLOGY. 2019, **203**, 3045-3053.
- [120]. Wang, X., Cao, Q., Yu, L. et al. Epigenetic regulation of macrophage polarization and inflammation by DNA methylation in obesity [J] JCI INSIGHT. 2016, **1**, e87748.
- [121]. Yu, J., Qiu, Y., Yang, J. et al. DNMT1-PPAR $\gamma$  pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice [J] SCIENTIFIC REPORTS. 2016, **6**, 30053.
- [122]. Zhou, D., Yang, K., Chen, L. et al. Promising landscape for regulating macrophage polarization: epigenetic viewpoint [J] ONCOTARGET. 2017, **8**, 57693-57706.
- [123]. Zhong, Y., Huang, T., Huang, J. et al. The HDAC10 instructs macrophage M2 program via deacetylation of STAT3 and promotes allergic airway inflammation [J] THERANOSTICS. 2023, **13**, 3568-3581.
- [124]. Shi, Y., Li, J., Chen, H. et al. Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization [J] FRONTIERS IN IMMUNOLOGY. 2022, **13**, 899140.
- [125]. Li, M. L., Su, X. M., Ren, Y. et al. HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization [J] RESPIRATORY RESEARCH. 2020, **21**, 62.
- [126]. Zhou, X., Chen, H., Shi, Y. et al. Histone deacetylase 8 inhibition prevents the progression of peritoneal fibrosis by counteracting the epithelial-mesenchymal transition and blockade of M2 macrophage polarization [J] FRONTIERS IN IMMUNOLOGY. 2023, **14**, 1137332.
- [127]. Yan, B., Xie, S., Liu, Z. et al. HDAC6 deacetylase activity is critical for lipopolysaccharide-induced activation of macrophages [J] PLOS ONE. 2014, **9**, e110718.
- [128]. Ishii, M., Wen, H., Corsa, C. A. et al. Epigenetic regulation of the alternatively activated macrophage phenotype [J] BLOOD. 2009, **114**, 3244-3254.
- [129]. Chen, J., Xu, X., Li, Y. et al. Kdm6a suppresses the alternative activation of macrophages and impairs energy expenditure in obesity [J] CELL DEATH & DIFFERENTIATION. 2021, **28**, 1688-1704.

- [130]. Zhong, C., Tao, B., Yang, F. et al. Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a [J] *CLINICAL AND TRANSLATIONAL MEDICINE*. 2021, **11**, e424.
- [131]. Hachiya, R., Shiihashi, T., Shirakawa, I. et al. The H3K9 methyltransferase Setdb1 regulates TLR4-mediated inflammatory responses in macrophages [J] *SCIENTIFIC REPORTS*. 2016, **6**, 28845.
- [132]. Zhang, Y., Gao, Y., Jiang, Y. et al. Histone demethylase KDM5B licenses macrophage-mediated inflammatory responses by repressing Nfkbia transcription [J] *CELL DEATH & DIFFERENTIATION*. 2023, **30**, 1279-1292.
- [133]. Hardbower, D. M., Asim, M., Luis, P. B. et al. Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications [J] *PROC NATL ACAD SCI U S A*. 2017, **114**, E751-e760.
- [134]. Nguyen, H. C. B., Adlanmerini, M., Hauck, A. K. et al. Dichotomous engagement of HDAC3 activity governs inflammatory responses [J] *Nature*. 2020, **584**, 286-290.
- [135]. Tikhanovich, I., Zhao, J., Bridges, B. et al. Arginine methylation regulates c-Myc-dependent transcription by altering promoter recruitment of the acetyltransferase p300 [J] *JOURNAL OF BIOLOGICAL CHEMISTRY*. 2017, **292**, 13333-13344.
- [136]. Qin, Y., Li, B., Arumugam, S. et al. m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity [J] *Cell Rep*. 2021, **37**, 109968.
- [137]. Liu, Y., Liu, Z., Tang, H. et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA [J] *AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY*. 2019, **317**, C762-C775.
- [138]. Li, Z., Xu, Q., Huangfu, N. et al. Mettl3 promotes oxLDL-mediated inflammation through activating STAT1 signaling [J] *JOURNAL OF CLINICAL LABORATORY ANALYSIS*. 2022, **36**, e24019.
- [139]. Pan, X.-s., Li, B.-w., Wang, L.-l. et al. Kupffer cell pyroptosis mediated by METTL3 contributes to the progression of alcoholic steatohepatitis [J] *FASEB JOURNAL*. 2023, **37**, e22965.
- [140]. Han, X., Liu, L., Huang, S. et al. RNA m(6)A methylation modulates airway inflammation in allergic asthma via PTX3-dependent macrophage homeostasis [J] *NATURE COMMUNICATIONS*. 2023, **14**, 7328.
- [141]. Zheng, Y., Li, Y., Ran, X. et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF- $\kappa$ B/IL-6 signaling pathway [J] *CELLULAR AND MOLECULAR LIFE SCIENCES*. 2022, **79**, 311.
- [142]. Li, Y., Li, J., Yu, Q. et al. METTL14 regulates microglia/macrophage polarization and NLRP3 inflammasome activation after ischemic stroke by the KAT3B-STING axis [J] *NEUROBIOLOGY OF DISEASE*. 2023, **185**, 106253.
- [143]. Wang, X., Ding, Y., Li, R. et al. N(6)-methyladenosine of Spi2a attenuates inflammation and sepsis-associated myocardial dysfunction in mice [J] *NATURE COMMUNICATIONS*. 2023, **14**, 1185.
- [144]. Du, J., Liao, W., Liu, W. et al. N(6)-Adenosine Methylation of Socs1 mRNA Is Required to Sustain the Negative Feedback Control of Macrophage Activation [J] *DEVELOPMENTAL CELL*. 2020, **55**, 737-753.e737.
- [145]. Gu, X., Zhang, Y., Li, D. et al. N6-methyladenosine demethylase FTO promotes M1 and M2



- macrophage activation [J] *CELLULAR SIGNALLING*. 2020, **69**, 109553.
- [146]. Tan, J., Chen, F., Wang, J. et al. ALKBH5 promotes the development of lung adenocarcinoma by regulating the polarization of M2 macrophages through CDCA4 [J] *GENE*. 2024, **895**, 147975.
- [147]. Hu, L., Yu, Y., Shen, Y. et al. Ythdf2 promotes pulmonary hypertension by suppressing Hmox1-dependent anti-inflammatory and antioxidant function in alveolar macrophages [J] *REDOX BIOLOGY*. 2023, **61**, 102638.
- [148]. Huangfu, N., Zheng, W., Xu, Z. et al. RBM4 regulates M1 macrophages polarization through targeting STAT1-mediated glycolysis [J] *INTERNATIONAL IMMUNOPHARMACOLOGY*. 2020, **83**, 106432.
- [149]. Ma, D., Zhou, X., Wang, Y. et al. Changes in the Small Noncoding RNAome During M1 and M2 Macrophage Polarization [J] *FRONTIERS IN IMMUNOLOGY*. 2022, **13**, 799733.
- [150]. Hu, J., Zhang, L., Liechty, C. et al. Long Noncoding RNA GAS5 Regulates Macrophage Polarization and Diabetic Wound Healing [J] *JOURNAL OF INVESTIGATIVE DERMATOLOGY*. 2020, **140**, 1629-1638.
- [151]. Peng, K., Biao, C., Zhao, Y. Y. et al. Long non-coding RNA MM2P suppresses M1-polarized macrophages-mediated excessive inflammation to prevent sodium taurocholate-induced acute pancreatitis by blocking SHP2-mediated STAT3 dephosphorylation [J] *CLINICAL AND EXPERIMENTAL MEDICINE*. 2023, **23**, 3589-3603.
- [152]. Jia, Y., Li, Z., Cai, W. et al. SIRT1 regulates inflammation response of macrophages in sepsis mediated by long noncoding RNA [J] *BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - MOLECULAR BASIS OF DISEASE*. 2018, **1864**, 784-792.
- [153]. Li, X., Zhang, Y., Pei, W. et al. LncRNA Dnmt3aos regulates Dnmt3a expression leading to aberrant DNA methylation in macrophage polarization [J] *FASEB JOURNAL*. 2020, **34**, 5077-5091.
- [154]. Pei, W., Zhang, Y., Li, X. et al. LncRNA AK085865 depletion ameliorates asthmatic airway inflammation by modulating macrophage polarization [J] *INTERNATIONAL IMMUNOPHARMACOLOGY*. 2020, **83**, 106450.
- [155]. Gao, Y., Fang, P., Li, W. J. et al. LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma [J] *MOLECULAR IMMUNOLOGY*. 2020, **117**, 20-28.
- [156]. Qi, X., Wang, H., Xia, L. et al. miR-30b-5p releases HMGB1 via UBE2D2/KAT2B/HMGB1 pathway to promote pro-inflammatory polarization and recruitment of macrophages [J] *ATHEROSCLEROSIS*. 2021, **324**, 38-45.
- [157]. Roquilly, A., Mintern, J. D. & Villadangos, J. A. Spatiotemporal Adaptations of Macrophage and Dendritic Cell Development and Function [J] *ANNUAL REVIEW OF IMMUNOLOGY*. 2022, **40**, 525-557.
- [158]. Boe, D. M., Hulsebus, H. J., Najarro, K. M. et al. Advanced age is associated with changes in alveolar macrophages and their responses to the stress of traumatic injury [J] *JOURNAL OF LEUKOCYTE BIOLOGY* 2022, **112**, 1371-1386.
- [159]. Belz, G. T. & Nutt, S. L. Transcriptional programming of the dendritic cell network [J] *NATURE REVIEWS IMMUNOLOGY*. 2012, **12**, 101-113.
- [160]. Paul, F. & Amit, I. Plasticity in the transcriptional and epigenetic circuits regulating dendritic cell lineage specification and function [J] *CURRENT OPINION IN IMMUNOLOGY*. 2014,



**30**, 1-8.

- [161]. Lin, Q., Chauvistré, H., Costa, I. G. et al. Epigenetic program and transcription factor circuitry of dendritic cell development [J] *NUCLEIC ACIDS RESEARCH*. 2015, **43**, 9680-9693.
- [162]. Boukhalel, G. M., Corrado, M., Guak, H. et al. Chromatin Architecture as an Essential Determinant of Dendritic Cell Function [J] *FRONTIERS IN IMMUNOLOGY*. 2019, **10**, 1119.
- [163]. Vento-Tormo, R., Company, C., Rodríguez-Ubreva, J. et al. IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation [J] *GENOME BIOLOGY*. 2016, **17**, 4.
- [164]. Won, H., Nandakumar, V., Yates, P. et al. Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by *Mysm1* [J] *BLOOD*. 2014, **124**, 2647-2656.
- [165]. Becker, A. M., Michael, D. G., Satpathy, A. T. et al. IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors [J] *BLOOD*. 2012, **119**, 2003-2012.
- [166]. Kurotaki, D., Kawase, W., Sasaki, H. et al. Epigenetic control of early dendritic cell lineage specification by the transcription factor IRF8 in mice [J] *BLOOD*. 2019, **133**, 1803-1813.
- [167]. Lee, J., Zhou, Y. J., Ma, W. et al. Lineage specification of human dendritic cells is marked by IRF8 expression in hematopoietic stem cells and multipotent progenitors [J] *NATURE IMMUNOLOGY*. 2017, **18**, 877-888.
- [168]. Chauvistré, H. & Seré, K. Epigenetic aspects of DC development and differentiation [J] *MOLECULAR IMMUNOLOGY*. 2020, **128**, 116-124.
- [169]. Xu, H., Li, Z., Kuo, C. C. et al. A lncRNA identifies *Irf8* enhancer element in negative feedback control of dendritic cell differentiation [J] *ELIFE*. 2023, **12**
- [170]. Søndergaard, J. N., Poghosyan, S., Hontelez, S. et al. DC-SCRIPT Regulates IL-10 Production in Human Dendritic Cells by Modulating NF- $\kappa$ Bp65 Activation [J] *JOURNAL OF IMMUNOLOGY*. 2015, **195**, 1498-1505.
- [171]. Zhang, Y., Wu, T., He, Z. et al. Regulation of pDC fate determination by histone deacetylase 3 [J] *ELIFE*. 2023, **12**
- [172]. Yang, Q., Wei, J., Zhong, L. et al. Cross talk between histone deacetylase 4 and STAT6 in the transcriptional regulation of arginase 1 during mouse dendritic cell differentiation [J] *MOLECULAR AND CELLULAR BIOLOGY*. 2015, **35**, 63-75.
- [173]. Sun, Y., Chin, Y. E., Weisiger, E. et al. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3 [J] *JOURNAL OF IMMUNOLOGY*. 2009, **182**, 5899-5903.
- [174]. Boukhalel, Giselle M., Cordeiro, B., Deblois, G. et al. The Transcriptional Repressor Polycomb Group Factor 6, PCGF6, Negatively Regulates Dendritic Cell Activation and Promotes Quiescence [J] *CELL REPORTS*. 2016, **16**, 1829-1837.
- [175]. Yin, R., Chang, J., Li, Y. et al. Differential m6A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function [J] *CELL STEM CELL*. 2022, **29**, 149-159.e147.
- [176]. Wang, H., Hu, X., Huang, M. et al. *Mettl3*-mediated mRNA m(6)A methylation promotes dendritic cell activation [J] *NATURE COMMUNICATIONS*. 2019, **10**, 1898.
- [177]. Bai, X., Wong, C. C., Pan, Y. et al. Loss of *YTHDF1* in gastric tumors restores sensitivity to

- antitumor immunity by recruiting mature dendritic cells [J] *THE JOURNAL FOR IMMUNOTHERAPY OF CANCER*. 2022, **10**
- [178]. Niu, L., Lou, F., Sun, Y. et al. A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentation [J] *SCIENCE ADVANCES*. 2020, **6**, eaaz2059.
- [179]. Xin, J., Li, J., Feng, Y. et al. Downregulation of long noncoding RNA HOTAIRM1 promotes monocyte/dendritic cell differentiation through competitively binding to endogenous miR-3960 [J] *ONCOTARGETS AND THERAPY*. 2017, **10**, 1307-1315.
- [180]. Worbs, T., Hammerschmidt, S. I. & Förster, R. Dendritic cell migration in health and disease [J] *NATURE REVIEWS IMMUNOLOGY*. 2017, **17**, 30-48.
- [181]. Dress, R. J., Wong, A. Y. W. & Ginhoux, F. Homeostatic control of dendritic cell numbers and differentiation [J] *IMMUNOLOGY AND CELL BIOLOGY*. 2018, **96**, 463-476.
- [182]. Ardouin, L., Luche, H., Chelbi, R. et al. Broad and Largely Concordant Molecular Changes Characterize Tolerogenic and Immunogenic Dendritic Cell Maturation in Thymus and Periphery [J] *IMMUNITY*. 2016, **45**, 305-318.
- [183]. Ohl, L., Mohaupt, M., Czeloth, N. et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions [J] *IMMUNITY*. 2004, **21**, 279-288.
- [184]. Ulvmar, M. H., Werth, K., Braun, A. et al. The atypical chemokine receptor CCRL1 shapes functional CCL21 gradients in lymph nodes [J] *NATURE IMMUNOLOGY*. 2014, **15**, 623-630.
- [185]. Förster, R., Davalos-Miszlitz, A. C. & Rot, A. CCR7 and its ligands: Balancing immunity and tolerance [J] *NATURE REVIEWS IMMUNOLOGY*. 2008, **8**, 362-371.
- [186]. Han, Y., Li, X., Zhou, Q. et al. FTY720 abrogates collagen-induced arthritis by hindering dendritic cell migration to local lymph nodes [J] *JOURNAL OF IMMUNOLOGY*. 2015, **195**, 4126-4135.
- [187]. Liu, J., Zhang, X., Chen, K. et al. CCR7 Chemokine Receptor-Inducible lnc-Dpf3 Restrains Dendritic Cell Migration by Inhibiting HIF-1 $\alpha$ -Mediated Glycolysis [J] *IMMUNITY*. 2019, **50**, 600-615.e615.
- [188]. Brubaker, S. W., Bonham, K. S., Zanoni, I. et al. Innate immune pattern recognition: a cell biological perspective [J] *ANNUAL REVIEW OF IMMUNOLOGY*. 2015, **33**, 257-290.
- [189]. Artis, D. & Spits, H. The biology of innate lymphoid cells [J] *NATURE*. 2015, **517**, 293-301.
- [190]. Cong, B., Zhang, Q. & Cao, X. The function and regulation of TET2 in innate immunity and inflammation [J] *PROTEIN CELL*. 2021, **12**, 165-173.
- [191]. Domínguez-Andrés, J., Dos Santos, J. C., Bekkering, S. et al. Trained immunity: adaptation within innate immune mechanisms [J] *PHYSIOLOGICAL REVIEWS*. 2023, **103**, 313-346.
- [192]. Michieletto, M. F., Tello-Cajiao, J. J., Mowel, W. K. et al. Multiscale 3D genome organization underlies ILC2 ontogenesis and allergic airway inflammation [J] *NATURE IMMUNOLOGY*. 2023, **24**, 42-54.
- [193]. Guo, X., Liang, Y., Zhang, Y. et al. Innate Lymphoid Cells Control Early Colonization Resistance against Intestinal Pathogens through ID2-Dependent Regulation of the Microbiota [J] *IMMUNITY*. 2015, **42**, 731-743.
- [194]. Mowel, W. K., McCright, S. J., Kotzin, J. J. et al. Group 1 Innate Lymphoid Cell Lineage Identity Is Determined by a cis-Regulatory Element Marked by a Long Non-coding RNA [J] *IMMUNITY*. 2017, **47**, 435-449.e438.

- [195]. Liu, B., Ye, B., Yang, L. et al. Long noncoding RNA lncKdm2b is required for ILC3 maintenance by initiation of Zfp292 expression [J] *NATURE IMMUNOLOGY*. 2017, **18**, 499-508.
- [196]. Liu, N., He, J., Fan, D. et al. Circular RNA circTmem241 drives group III innate lymphoid cell differentiation via initiation of Elk3 transcription [J] *NATURE COMMUNICATIONS*. 2022, **13**, 4711.
- [197]. Liu, B., Liu, N., Zhu, X. et al. Circular RNA circZbtb20 maintains ILC3 homeostasis and function via Alkbh5-dependent m(6)A demethylation of Nr4a1 mRNA [J] *CELLULAR & MOLECULAR IMMUNOLOGY*. 2021, **18**, 1412-1424.
- [198]. Zhang, Y., Zhang, W., Zhao, J. et al. m6A RNA modification regulates innate lymphoid cell responses in a lineage-specific manner [J] *NATURE IMMUNOLOGY*. 2023, **24**, 1256-1264.
- [199]. Yagi, R., Zhong, C., Northrup, D. L. et al. The transcription factor GATA3 is critical for the development of all IL-7R $\alpha$ -expressing innate lymphoid cells [J] *IMMUNITY*. 2014, **40**, 378-388.
- [200]. Summers, A. R., Fischer, M. A., Stengel, K. R. et al. HDAC3 is essential for DNA replication in hematopoietic progenitor cells [J] *JOURNAL OF CLINICAL INVESTIGATION*. 2013, **123**, 3112-3123.
- [201]. Toki, S., Goleniewska, K., Reiss, S. et al. The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation [J] *THORAX*. 2016, **71**, 633-645.
- [202]. Kerscher, B., Barlow, J. L., Rana, B. M. et al. BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation [J] *FRONTIERS IN IMMUNOLOGY*. 2019, **10**, 678.
- [203]. Antignano, F., Braam, M., Hughes, M. R. et al. G9a regulates group 2 innate lymphoid cell development by repressing the group 3 innate lymphoid cell program [J] *JOURNAL OF EXPERIMENTAL MEDICINE*. 2016, **213**, 1153-1162.
- [204]. Spooner, C. J., Lesch, J., Yan, D. et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1 [J] *NATURE IMMUNOLOGY*. 2013, **14**, 1229-1236.
- [205]. Duan, Z., Zarebski, A., Montoya-Durango, D. et al. Gfi1 coordinates epigenetic repression of p21Cip/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1 [J] *MOLECULAR AND CELLULAR BIOLOGY*. 2005, **25**, 10338-10351.
- [206]. Holmes, T. D., Pandey, R. V., Helm, E. Y. et al. The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation [J] *SCIENCE IMMUNOLOGY*. 2021, **6**, eabc9801.
- [207]. Victor, A. R., Weigel, C., Scoville, S. D. et al. Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development [J] *JOURNAL OF IMMUNOLOGY*. 2018, **200**, 565-572.
- [208]. Nandakumar, V., Chou, Y., Zang, L. et al. Epigenetic control of natural killer cell maturation by histone H2A deubiquitinase, MYSM1 [J] *PROC NATL ACAD SCI U S A*. 2013, **110**, E3927-3936.
- [209]. Cichocki, F., Felices, M., McCullar, V. et al. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling [J] *JOURNAL OF IMMUNOLOGY*. 2011, **187**, 6171-6175.
- [210]. Schenk, A., Bloch, W. & Zimmer, P. Natural Killer Cells--An Epigenetic Perspective of

- Development and Regulation [J] INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2016, **17**, 326.
- [211]. Lauterbach, M. A., Hanke, J. E., Serefidou, M. et al. Toll-like Receptor Signaling Rewires Macrophage Metabolism and Promotes Histone Acetylation via ATP-Citrate Lyase [J] IMMUNITY. 2019, **51**, 997-1011.e1017.
- [212]. Liu, Y., Zhang, Q., Ding, Y. et al. Histone lysine methyltransferase Ezh1 promotes TLR-triggered inflammatory cytokine production by suppressing Tollip [J] JOURNAL OF IMMUNOLOGY. 2015, **194**, 2838-2846.
- [213]. Yuan, J., Zhu, Q., Zhang, X. et al. Ezh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation [J] CELL DEATH & DIFFERENTIATION. 2022, **29**, 2009-2023.
- [214]. Xiao, Y., Zhao, C., Tai, Y. et al. STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome [J] REDOX BIOLOGY. 2023, **62**, 102691.
- [215]. Austenaa, L., Barozzi, I., Chronowska, A. et al. The histone methyltransferase Wbp7 controls macrophage function through GPI glycolipid anchor synthesis [J] IMMUNITY. 2012, **36**, 572-585.
- [216]. Chi, Z., Chen, S., Xu, T. et al. Histone Deacetylase 3 Couples Mitochondria to Drive IL-1 $\beta$ -Dependent Inflammation by Configuring Fatty Acid Oxidation [J] MOLECULAR CELL. 2020, **80**, 43-58.e47.
- [217]. Luo, S., Liao, C., Zhang, L. et al. METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling [J] CELL REPORTS. 2023, **42**, 112259.
- [218]. Xu, J., Liu, L. Y., Zhi, F. J. et al. DDX5 inhibits inflammation by modulating m6A levels of TLR2/4 transcripts during bacterial infection [J] EMBO REPORTS. 2024, **1**
- [219]. Zong, X., Xiao, X., Shen, B. et al. The N6-methyladenosine RNA-binding protein YTHDF1 modulates the translation of TRAF6 to mediate the intestinal immune response [J] NUCLEIC ACIDS RESEARCH. 2021, **49**, 5537-5552.
- [220]. Zong, X., Xiao, X., Jie, F. et al. YTHDF1 promotes NLRP3 translation to induce intestinal epithelial cell inflammatory injury during endotoxic shock [J] SCIENCE CHINA LIFE SCIENCES. 2021, **64**, 1988-1991.
- [221]. Hao, W. Y., Lou, Y., Hu, G. Y. et al. RNA m6A reader YTHDF1 facilitates inflammation via enhancing NLRP3 translation [J] BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2022, **616**, 76-81.
- [222]. Zheng, Q., Hou, J., Zhou, Y. et al. The RNA helicase DDX46 inhibits innate immunity by entrapping m(6)A-demethylated antiviral transcripts in the nucleus [J] NATURE IMMUNOLOGY. 2017, **18**, 1094-1103.
- [223]. Rupani, H., Martinez-Nunez, R. T., Dennison, P. et al. Toll-like Receptor 7 Is Reduced in Severe Asthma and Linked to an Altered MicroRNA Profile [J] AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2016, **194**, 26-37.
- [224]. Diebold, S. S., Kaisho, T., Hemmi, H. et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA [J] SCIENCE. 2004, **303**, 1529-1531.
- [225]. Chen, X., El Gazzar, M., Yoza, B. K. et al. The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance

- [J] JOURNAL OF BIOLOGICAL CHEMISTRY. 2009, **284**, 27857-27865.
- [226]. Zhong, Y., Ye, P., Mei, Z. et al. The novel methyltransferase SETD4 regulates TLR agonist-induced expression of cytokines through methylation of lysine 4 at histone 3 in macrophages [J] MOLECULAR IMMUNOLOGY. 2019, **114**, 179-188.
- [227]. Zhang, Q., Zhao, K., Shen, Q. et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 [J] NATURE. 2015, **525**, 389-393.
- [228]. Zhang, Y., Li, H., Xiang, X. et al. Identification of DNMT3B2 as the Predominant Isoform of DNMT3B in Porcine Alveolar Macrophages and Its Involvement in LPS-Stimulated TNF- $\alpha$  Expression. *Genes* **11** (2020).
- [229]. Gong, X., Liang, Y., Wang, J. et al. Highly pathogenic PRRSV upregulates IL-13 production through nonstructural protein 9-mediated inhibition of N6-methyladenosine demethylase FTO [J] Journal of Biological Chemistry. 2024, **300**, 107199.
- [230]. Lyu, W., Deng, Z. & Zhang, G. High-Throughput Screening for Epigenetic Compounds That Induce Human  $\beta$ -Defensin 1 Synthesis [J] ANTIBIOTICS. 2023, **12**
- [231]. Rodríguez-Carlos, A., Jacobo-Delgado, Y. M., Santos-Mena, A. O. et al. Modulation of cathelicidin and defensins by histone deacetylase inhibitors: A potential treatment for multi-drug resistant infectious diseases [J] PEPTIDES. 2021, **140**, 170527.
- [232]. Garcia-Garcia, J. C., Barat, N. C., Trembley, S. J. et al. Epigenetic silencing of host cell defense genes enhances intracellular survival of the rickettsial pathogen *Anaplasma phagocytophilum* [J] PLOS PATHOGENS. 2009, **5**, e1000488.
- [233]. Fischer, N., Sechet, E., Friedman, R. et al. Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge [J] PROC NATL ACAD SCI U S A. 2016, **113**, E2993-3001.
- [234]. Wang, G., Li, Y., Yang, G. et al. Cathelicidin antimicrobial peptide (CAMP) gene promoter methylation induces chondrocyte apoptosis [J] HUMAN GENOMICS. 2021, **15**, 24.
- [235]. Chen, X., Qi, G., Qin, M. et al. DNA methylation directly downregulates human cathelicidin antimicrobial peptide gene (CAMP) promoter activity [J] ONCOTARGET. 2017, **8**, 27943-27952.
- [236]. Noh, Y. H., Lee, J., Seo, S. J. et al. Promoter DNA methylation contributes to human  $\beta$ -defensin-1 deficiency in atopic dermatitis [J] ANIMAL CELLS AND SYSTEMS. 2018, **22**, 172-177.
- [237]. Zong, X., Wang, H., Xiao, X. et al. Enterotoxigenic *Escherichia coli* infection promotes enteric defensin expression via FOXO6-METTL3-m(6)A-GPR161 signalling axis [J] RNA BIOLOGY. 2021, **18**, 576-586.
- [238]. Bowling, S., Sritharan, D., Osorio, F. G. et al. An Engineered CRISPR-Cas9 Mouse Line for Simultaneous Readout of Lineage Histories and Gene Expression Profiles in Single Cells [J] CELL. 2020, **181**, 1410-1422.e1427.